Pharmacokinetics and dosage adjustment in patients with renal dysfunction
Introduction Chronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the renal excretion of parent drug and/or its metabolites will be impaired, leading to their excessive accumulation in the body. In addition, the...
Saved in:
| Published in | European journal of clinical pharmacology Vol. 65; no. 8; pp. 757 - 773 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Berlin/Heidelberg : Springer-Verlag
01.08.2009
Springer-Verlag Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0031-6970 1432-1041 1432-1041 |
| DOI | 10.1007/s00228-009-0678-8 |
Cover
Loading…
| Abstract | Introduction Chronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the renal excretion of parent drug and/or its metabolites will be impaired, leading to their excessive accumulation in the body. In addition, the plasma protein binding of drugs may be significantly reduced, which in turn could influence the pharmacokinetic processes of distribution and elimination. The activity of several drug-metabolizing enzymes and drug transporters has been shown to be impaired in chronic renal failure. In patients with end-stage renal disease, dialysis techniques such as hemodialysis and continuous ambulatory peritoneal dialysis may remove drugs from the body, necessitating dosage adjustment. Methods Inappropriate dosing in patients with renal dysfunction can cause toxicity or ineffective therapy. Therefore, the normal dosage regimen of a drug may have to be adjusted in a patient with renal dysfunction. Dosage adjustment is based on the remaining kidney function, most often estimated on the basis of the patient's glomerular filtration rate (GFR) estimated by the Cockroft-Gault formula. Net renal excretion of drug is a combination of three processes: glomerular filtration, tubular secretion and tubular reabsorption. Therefore, dosage adjustment based on GFR may not always be appropriate and a re-evaluation of markers of renal function may be required. Discussion According to EMEA and FDA guidelines, a pharmacokinetic study should be carried out during the development phase of a new drug that is likely to be used in patients with renal dysfunction and whose pharmacokinetics are likely to be significantly altered in these patients. This study should be carried out in carefully selected subjects with varying degrees of renal dysfunction. In addition to this two-stage pharmacokinetic approach, a population PK/PD study in patients participating in phase II/phase III clinical trials can also be used to assess the impact of renal dysfunction on the drug's pharmacokinetics and pharmacodynamics. Conclusion In conclusion, renal dysfunction affects more that just the renal handling of drugs and/or active drug metabolites. Even when the dosage adjustment recommended for patients with renal dysfunction are carefully followed, adverse drug reactions remain common. |
|---|---|
| AbstractList | Chronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the renal excretion of parent drug and/or its metabolites will be impaired, leading to their excessive accumulation in the body. In addition, the plasma protein binding of drugs may be significantly reduced, which in turn could influence the pharmacokinetic processes of distribution and elimination. The activity of several drug-metabolizing enzymes and drug transporters has been shown to be impaired in chronic renal failure. In patients with end-stage renal disease, dialysis techniques such as hemodialysis and continuous ambulatory peritoneal dialysis may remove drugs from the body, necessitating dosage adjustment.
Inappropriate dosing in patients with renal dysfunction can cause toxicity or ineffective therapy. Therefore, the normal dosage regimen of a drug may have to be adjusted in a patient with renal dysfunction. Dosage adjustment is based on the remaining kidney function, most often estimated on the basis of the patient's glomerular filtration rate (GFR) estimated by the Cockroft-Gault formula. Net renal excretion of drug is a combination of three processes: glomerular filtration, tubular secretion and tubular reabsorption. Therefore, dosage adjustment based on GFR may not always be appropriate and a re-evaluation of markers of renal function may be required.
According to EMEA and FDA guidelines, a pharmacokinetic study should be carried out during the development phase of a new drug that is likely to be used in patients with renal dysfunction and whose pharmacokinetics are likely to be significantly altered in these patients. This study should be carried out in carefully selected subjects with varying degrees of renal dysfunction. In addition to this two-stage pharmacokinetic approach, a population PK/PD study in patients participating in phase II/phase III clinical trials can also be used to assess the impact of renal dysfunction on the drug's pharmacokinetics and pharmacodynamics.
In conclusion, renal dysfunction affects more that just the renal handling of drugs and/or active drug metabolites. Even when the dosage adjustment recommended for patients with renal dysfunction are carefully followed, adverse drug reactions remain common. Introduction Chronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the renal excretion of parent drug and/or its metabolites will be impaired, leading to their excessive accumulation in the body. In addition, the plasma protein binding of drugs may be significantly reduced, which in turn could influence the pharmacokinetic processes of distribution and elimination. The activity of several drug-metabolizing enzymes and drug transporters has been shown to be impaired in chronic renal failure. In patients with end-stage renal disease, dialysis techniques such as hemodialysis and continuous ambulatory peritoneal dialysis may remove drugs from the body, necessitating dosage adjustment. Methods Inappropriate dosing in patients with renal dysfunction can cause toxicity or ineffective therapy. Therefore, the normal dosage regimen of a drug may have to be adjusted in a patient with renal dysfunction. Dosage adjustment is based on the remaining kidney function, most often estimated on the basis of the patient's glomerular filtration rate (GFR) estimated by the Cockroft–Gault formula. Net renal excretion of drug is a combination of three processes: glomerular filtration, tubular secretion and tubular reabsorption. Therefore, dosage adjustment based on GFR may not always be appropriate and a re-evaluation of markers of renal function may be required. Discussion According to EMEA and FDA guidelines, a pharmacokinetic study should be carried out during the development phase of a new drug that is likely to be used in patients with renal dysfunction and whose pharmacokinetics are likely to be significantly altered in these patients. This study should be carried out in carefully selected subjects with varying degrees of renal dysfunction. In addition to this two-stage pharmacokinetic approach, a population PK/PD study in patients participating in phase II/phase III clinical trials can also be used to assess the impact of renal dysfunction on the drug's pharmacokinetics and pharmacodynamics. Conclusion In conclusion, renal dysfunction affects more that just the renal handling of drugs and/or active drug metabolites. Even when the dosage adjustment recommended for patients with renal dysfunction are carefully followed, adverse drug reactions remain common. Chronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the renal excretion of parent drug and/or its metabolites will be impaired, leading to their excessive accumulation in the body. In addition, the plasma protein binding of drugs may be significantly reduced, which in turn could influence the pharmacokinetic processes of distribution and elimination. The activity of several drug-metabolizing enzymes and drug transporters has been shown to be impaired in chronic renal failure. In patients with end-stage renal disease, dialysis techniques such as hemodialysis and continuous ambulatory peritoneal dialysis may remove drugs from the body, necessitating dosage adjustment. Inappropriate dosing in patients with renal dysfunction can cause toxicity or ineffective therapy. Therefore, the normal dosage regimen of a drug may have to be adjusted in a patient with renal dysfunction. Dosage adjustment is based on the remaining kidney function, most often estimated on the basis of the patient's glomerular filtration rate (GFR) estimated by the Cockroft-Gault formula. Net renal excretion of drug is a combination of three processes: glomerular filtration, tubular secretion and tubular reabsorption. Therefore, dosage adjustment based on GFR may not always be appropriate and a re-evaluation of markers of renal function may be required. According to EMEA and FDA guidelines, a pharmacokinetic study should be carried out during the development phase of a new drug that is likely to be used in patients with renal dysfunction and whose pharmacokinetics are likely to be significantly altered in these patients. This study should be carried out in carefully selected subjects with varying degrees of renal dysfunction. In addition to this two-stage pharmacokinetic approach, a population PK/PD study in patients participating in phase II/phase III clinical trials can also be used to assess the impact of renal dysfunction on the drug's pharmacokinetics and pharmacodynamics. In conclusion, renal dysfunction affects more that just the renal handling of drugs and/or active drug metabolites. Even when the dosage adjustment recommended for patients with renal dysfunction are carefully followed, adverse drug reactions remain common. [PUBLICATION ABSTRACT] Introduction Chronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the renal excretion of parent drug and/or its metabolites will be impaired, leading to their excessive accumulation in the body. In addition, the plasma protein binding of drugs may be significantly reduced, which in turn could influence the pharmacokinetic processes of distribution and elimination. The activity of several drug-metabolizing enzymes and drug transporters has been shown to be impaired in chronic renal failure. In patients with end-stage renal disease, dialysis techniques such as hemodialysis and continuous ambulatory peritoneal dialysis may remove drugs from the body, necessitating dosage adjustment. Methods Inappropriate dosing in patients with renal dysfunction can cause toxicity or ineffective therapy. Therefore, the normal dosage regimen of a drug may have to be adjusted in a patient with renal dysfunction. Dosage adjustment is based on the remaining kidney function, most often estimated on the basis of the patient's glomerular filtration rate (GFR) estimated by the Cockroft-Gault formula. Net renal excretion of drug is a combination of three processes: glomerular filtration, tubular secretion and tubular reabsorption. Therefore, dosage adjustment based on GFR may not always be appropriate and a re-evaluation of markers of renal function may be required. Discussion According to EMEA and FDA guidelines, a pharmacokinetic study should be carried out during the development phase of a new drug that is likely to be used in patients with renal dysfunction and whose pharmacokinetics are likely to be significantly altered in these patients. This study should be carried out in carefully selected subjects with varying degrees of renal dysfunction. In addition to this two-stage pharmacokinetic approach, a population PK/PD study in patients participating in phase II/phase III clinical trials can also be used to assess the impact of renal dysfunction on the drug's pharmacokinetics and pharmacodynamics. Conclusion In conclusion, renal dysfunction affects more that just the renal handling of drugs and/or active drug metabolites. Even when the dosage adjustment recommended for patients with renal dysfunction are carefully followed, adverse drug reactions remain common. Chronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the renal excretion of parent drug and/or its metabolites will be impaired, leading to their excessive accumulation in the body. In addition, the plasma protein binding of drugs may be significantly reduced, which in turn could influence the pharmacokinetic processes of distribution and elimination. The activity of several drug-metabolizing enzymes and drug transporters has been shown to be impaired in chronic renal failure. In patients with end-stage renal disease, dialysis techniques such as hemodialysis and continuous ambulatory peritoneal dialysis may remove drugs from the body, necessitating dosage adjustment.INTRODUCTIONChronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the renal excretion of parent drug and/or its metabolites will be impaired, leading to their excessive accumulation in the body. In addition, the plasma protein binding of drugs may be significantly reduced, which in turn could influence the pharmacokinetic processes of distribution and elimination. The activity of several drug-metabolizing enzymes and drug transporters has been shown to be impaired in chronic renal failure. In patients with end-stage renal disease, dialysis techniques such as hemodialysis and continuous ambulatory peritoneal dialysis may remove drugs from the body, necessitating dosage adjustment.Inappropriate dosing in patients with renal dysfunction can cause toxicity or ineffective therapy. Therefore, the normal dosage regimen of a drug may have to be adjusted in a patient with renal dysfunction. Dosage adjustment is based on the remaining kidney function, most often estimated on the basis of the patient's glomerular filtration rate (GFR) estimated by the Cockroft-Gault formula. Net renal excretion of drug is a combination of three processes: glomerular filtration, tubular secretion and tubular reabsorption. Therefore, dosage adjustment based on GFR may not always be appropriate and a re-evaluation of markers of renal function may be required.METHODSInappropriate dosing in patients with renal dysfunction can cause toxicity or ineffective therapy. Therefore, the normal dosage regimen of a drug may have to be adjusted in a patient with renal dysfunction. Dosage adjustment is based on the remaining kidney function, most often estimated on the basis of the patient's glomerular filtration rate (GFR) estimated by the Cockroft-Gault formula. Net renal excretion of drug is a combination of three processes: glomerular filtration, tubular secretion and tubular reabsorption. Therefore, dosage adjustment based on GFR may not always be appropriate and a re-evaluation of markers of renal function may be required.According to EMEA and FDA guidelines, a pharmacokinetic study should be carried out during the development phase of a new drug that is likely to be used in patients with renal dysfunction and whose pharmacokinetics are likely to be significantly altered in these patients. This study should be carried out in carefully selected subjects with varying degrees of renal dysfunction. In addition to this two-stage pharmacokinetic approach, a population PK/PD study in patients participating in phase II/phase III clinical trials can also be used to assess the impact of renal dysfunction on the drug's pharmacokinetics and pharmacodynamics.DISCUSSIONAccording to EMEA and FDA guidelines, a pharmacokinetic study should be carried out during the development phase of a new drug that is likely to be used in patients with renal dysfunction and whose pharmacokinetics are likely to be significantly altered in these patients. This study should be carried out in carefully selected subjects with varying degrees of renal dysfunction. In addition to this two-stage pharmacokinetic approach, a population PK/PD study in patients participating in phase II/phase III clinical trials can also be used to assess the impact of renal dysfunction on the drug's pharmacokinetics and pharmacodynamics.In conclusion, renal dysfunction affects more that just the renal handling of drugs and/or active drug metabolites. Even when the dosage adjustment recommended for patients with renal dysfunction are carefully followed, adverse drug reactions remain common.CONCLUSIONIn conclusion, renal dysfunction affects more that just the renal handling of drugs and/or active drug metabolites. Even when the dosage adjustment recommended for patients with renal dysfunction are carefully followed, adverse drug reactions remain common. |
| Author | Musuamba, Flora T Verbeeck, Roger K |
| Author_xml | – sequence: 1 fullname: Verbeeck, Roger K – sequence: 2 fullname: Musuamba, Flora T |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21752300$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19543887$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkd1rFDEUxYNU7Lb6B_iig6Bvozefk3ksxY9CQUH7HLI3mW3W2cyaZJD-92aZ1UIfKgSSh9-5N-ecM3ISp-gJeUnhPQXoPmQAxnQL0LegOt3qJ2RFBWctBUFPyAqA01b1HZySs5y3AFT2wJ-RU9pLwbXuVuTq261NO4vTzxB9CZgbG13jpmw3vrFuO-ey87E0ITZ7W0J95uZ3KLdN8tGOjbvLwxyxhCk-J08HO2b_4nifk5tPH39cfmmvv36-ury4blF0fWmZFyDVuncCuZRa9s6tvbKoOu4QKXDUWkolUTAJCGtg2NPecYFSU4rIz8m7Ze4-Tb9mn4vZhYx-HG3005yN6iRV9fwXFIozpRRU8M0DcDvNqdrLhlFRf12Dq9CrIzSvd96ZfQo7m-7M3ygr8PYI2Ix2HJKNGPI_jtFOMg6HbXThME05Jz_cjwJzqNUstZpaqznUanTVdA80GIo9pF6SDeOjSrYoc90SNz7de3tM9HoRDXYydpOqjZvvrIYANVndMcH_AMvevVE |
| CitedBy_id | crossref_primary_10_1016_j_cpha_2015_09_003 crossref_primary_10_1111_cts_70110 crossref_primary_10_1128_AAC_03359_14 crossref_primary_10_4103_1319_2442_270263 crossref_primary_10_1007_s11096_015_0175_3 crossref_primary_10_3390_pharmaceutics15051424 crossref_primary_10_1186_1752_0509_7_S3_S3 crossref_primary_10_1124_dmd_116_074492 crossref_primary_10_3390_jpm10030056 crossref_primary_10_1007_s00280_010_1366_1 crossref_primary_10_1186_s40545_023_00606_4 crossref_primary_10_1186_s40360_018_0221_6 crossref_primary_10_1002_14651858_CD009440_pub2 crossref_primary_10_1155_2014_108185 crossref_primary_10_1186_1471_2369_15_204 crossref_primary_10_1007_s11095_016_2033_y crossref_primary_10_1016_j_clinthera_2015_09_016 crossref_primary_10_1016_j_ctmp_2024_200178 crossref_primary_10_1016_j_isci_2022_103834 crossref_primary_10_1016_j_taap_2022_116140 crossref_primary_10_1111_tri_12359 crossref_primary_10_1002_elan_202100630 crossref_primary_10_1177_875512251302900407 crossref_primary_10_1007_s13318_018_0501_y crossref_primary_10_3390_ani12030262 crossref_primary_10_1007_s11096_015_0182_4 crossref_primary_10_1007_s40262_024_01453_5 crossref_primary_10_1016_j_jenvman_2024_120170 crossref_primary_10_1002_wfs2_1297 crossref_primary_10_1093_jamia_ocaa222 crossref_primary_10_1093_ndt_gfad038 crossref_primary_10_1002_cpt_2642 crossref_primary_10_1590_s2175_97902019000318296 crossref_primary_10_1111_1753_0407_13534 crossref_primary_10_1093_jac_dky078 crossref_primary_10_1186_1471_2369_15_46 crossref_primary_10_1007_s40261_014_0237_7 crossref_primary_10_1016_j_medin_2015_07_009 crossref_primary_10_1016_j_cpha_2015_09_011 crossref_primary_10_1093_qjmed_hcx086 crossref_primary_10_1055_s_0040_1721056 crossref_primary_10_1016_j_ejps_2023_106395 crossref_primary_10_1111_1759_7714_14357 crossref_primary_10_3389_fphar_2020_00883 crossref_primary_10_1007_s40266_018_0563_1 crossref_primary_10_1093_ndt_gfr616 crossref_primary_10_18231_j_ijpp_2020_021 crossref_primary_10_1016_j_medine_2015_07_001 crossref_primary_10_1002_bmc_3767 crossref_primary_10_1016_j_clinthera_2014_12_013 crossref_primary_10_1111_bcp_15132 crossref_primary_10_1186_s12885_024_12291_w crossref_primary_10_1517_17425255_2010_494597 crossref_primary_10_3389_fphar_2019_00641 crossref_primary_10_1160_TH14_06_0547 crossref_primary_10_1371_journal_pbio_3000987 crossref_primary_10_1086_685017 crossref_primary_10_1053_j_ackd_2010_05_010 crossref_primary_10_1111_j_1365_2125_2011_03992_x crossref_primary_10_1007_s11940_018_0530_5 crossref_primary_10_1016_j_xphs_2023_03_008 crossref_primary_10_1093_ndt_gfv320 crossref_primary_10_1053_j_ajkd_2014_09_015 crossref_primary_10_1111_bcp_12542 crossref_primary_10_1177_0091270011431457 crossref_primary_10_1007_s40620_023_01665_1 crossref_primary_10_1177_1060028013503131 crossref_primary_10_1159_000353261 crossref_primary_10_1177_1179559X18777767 crossref_primary_10_1007_s11164_014_1780_9 crossref_primary_10_1016_j_cmi_2020_11_032 crossref_primary_10_1007_s40262_013_0055_8 crossref_primary_10_1016_j_critrevonc_2011_02_006 crossref_primary_10_1038_nrneph_2010_43 crossref_primary_10_33549_physiolres_933374 crossref_primary_10_1684_bdc_2011_1483 crossref_primary_10_1016_j_bbadis_2012_09_006 crossref_primary_10_1016_j_dialis_2011_07_001 crossref_primary_10_1002_cpt_758 crossref_primary_10_1586_era_11_2 crossref_primary_10_1002_jcph_2212 crossref_primary_10_1371_journal_pone_0158677 crossref_primary_10_1007_s00280_017_3378_6 crossref_primary_10_1016_S0304_5412_11_70106_8 crossref_primary_10_2147_DDDT_S249098 crossref_primary_10_1007_s40258_018_0426_2 crossref_primary_10_1007_s40262_017_0574_9 crossref_primary_10_12687_phleb2290_6_2015 crossref_primary_10_1002_cpt_750 crossref_primary_10_5005_jp_journals_10049_0012 crossref_primary_10_1186_1471_2369_12_35 crossref_primary_10_1371_journal_pone_0106517 crossref_primary_10_1111_cts_13810 crossref_primary_10_1111_jcpt_12724 crossref_primary_10_7759_cureus_60092 crossref_primary_10_1159_000381012 crossref_primary_10_1208_s12248_024_00962_2 crossref_primary_10_1097_ACO_0b013e32833c5ccf crossref_primary_10_1007_s00228_010_0866_6 crossref_primary_10_1517_17425255_2010_482930 crossref_primary_10_1097_CAD_0000000000000513 crossref_primary_10_1186_s12877_021_02057_5 crossref_primary_10_1371_journal_pone_0216297 crossref_primary_10_3390_toxins11040209 crossref_primary_10_1016_j_jcrc_2023_154402 crossref_primary_10_1016_j_ancard_2014_04_006 crossref_primary_10_1007_s00467_019_04304_9 crossref_primary_10_1007_s00228_009_0766_9 crossref_primary_10_1016_S1470_2045_19_30145_7 crossref_primary_10_3803_EnM_2024_1965 crossref_primary_10_1007_s40262_013_0042_0 crossref_primary_10_1007_s40265_018_0980_9 crossref_primary_10_2147_DDDT_S362607 crossref_primary_10_1038_ki_2011_322 crossref_primary_10_1111_bcp_12917 crossref_primary_10_1097_01_JAA_0000435257_26357_a8 crossref_primary_10_1208_s12248_014_9687_3 crossref_primary_10_1002_jcph_247 crossref_primary_10_1136_ejhpharm_2020_002395 crossref_primary_10_1016_j_jchromb_2015_07_035 crossref_primary_10_1586_ern_11_181 crossref_primary_10_1080_17425255_2017_1292252 crossref_primary_10_1038_ki_2010_475 crossref_primary_10_3390_ph18030425 crossref_primary_10_1186_s40001_024_01972_8 crossref_primary_10_1002_cpt_1875 crossref_primary_10_1111_cts_13194 crossref_primary_10_3390_mi7070126 crossref_primary_10_1177_0091270011409231 crossref_primary_10_1002_jat_4078 crossref_primary_10_1111_sdi_12371 crossref_primary_10_1128_AAC_01372_12 crossref_primary_10_2147_JPR_S255345 crossref_primary_10_1007_s40264_016_0420_2 crossref_primary_10_1681_ASN_2017030361 crossref_primary_10_1111_j_1525_139X_2010_00773_x crossref_primary_10_1136_archdischild_2021_322781 crossref_primary_10_4155_bio_2022_0218 crossref_primary_10_3390_toxins12060391 crossref_primary_10_1186_s13643_021_01752_z crossref_primary_10_1021_acsomega_0c06165 crossref_primary_10_1016_j_ymeth_2016_07_023 crossref_primary_10_1177_20543581221129959 crossref_primary_10_1007_s40265_015_0452_4 crossref_primary_10_46405_ejms_v2i1_39 crossref_primary_10_1186_s12882_015_0155_9 crossref_primary_10_1007_s40262_013_0107_0 crossref_primary_10_1111_bcp_14881 crossref_primary_10_1002_bdd_2128 crossref_primary_10_1345_aph_1P676 crossref_primary_10_1002_cpdd_238 crossref_primary_10_1007_s00280_011_1802_x crossref_primary_10_1002_jppr_1450 crossref_primary_10_1002_phar_1836 crossref_primary_10_1517_17425255_2014_931371 crossref_primary_10_1161_CIRCULATIONAHA_111_084996 crossref_primary_10_1007_s40272_014_0101_5 crossref_primary_10_1007_s00228_017_2213_7 crossref_primary_10_1007_s00228_016_2086_1 crossref_primary_10_1155_2021_8238250 crossref_primary_10_1089_acm_2009_0563 crossref_primary_10_1016_j_jpba_2018_08_051 crossref_primary_10_1007_s00520_022_07235_8 crossref_primary_10_1016_j_addr_2014_05_007 crossref_primary_10_1016_j_mayocp_2015_01_016 crossref_primary_10_1111_sdi_12374 crossref_primary_10_1016_j_jsps_2024_102207 crossref_primary_10_1186_s12888_015_0531_9 crossref_primary_10_1007_s40262_016_0434_z crossref_primary_10_1371_journal_pone_0095991 crossref_primary_10_2147_DDDT_S387920 crossref_primary_10_3390_pharmacy8010033 crossref_primary_10_1248_bpb_b22_00025 crossref_primary_10_5649_jjphcs_39_660 crossref_primary_10_1007_s10147_023_02315_z crossref_primary_10_1016_j_nephro_2015_07_472 crossref_primary_10_2147_DDDT_S246229 crossref_primary_10_1111_bcp_12056 crossref_primary_10_1016_j_taap_2010_08_008 crossref_primary_10_1007_s00280_020_04084_2 crossref_primary_10_1080_17425255_2022_2132931 crossref_primary_10_1007_s40264_013_0017_y crossref_primary_10_1038_ki_2013_350 crossref_primary_10_3390_diseases12100249 crossref_primary_10_1016_j_acup_2015_09_002 crossref_primary_10_1016_j_mpaic_2018_12_006 crossref_primary_10_34067_KID_0001552022 crossref_primary_10_1016_j_mpaic_2021_10_014 crossref_primary_10_1124_jpet_121_000715 crossref_primary_10_1002_bmc_3505 |
| Cites_doi | 10.1016/S0049-3848(02)00031-2 10.1185/03007990802312807 10.1007/BF00543973 10.1046/j.1365-2125.1996.03864.x 10.1016/j.clinbiochem.2006.10.014 10.1067/mcp.2000.111934 10.2165/00003088-200847050-00004 10.2165/00003088-200342120-00003 10.1007/978-0-585-36947-1_30 10.1124/dmd.106.009258 10.1097/01.ASN.0000022011.35035.F3 10.1111/j.1542-4758.2007.00166.x 10.2165/00003088-200847080-00001 10.1016/0024-3205(87)90431-0 10.1681/ASN.2007090974 10.1053/j.ackd.2007.03.004 10.1111/j.1365-2125.2007.02917.x 10.1093/ndt/gfn028 10.1053/j.ajkd.2003.08.027 10.1016/j.clpt.2005.05.011 10.1038/sj.clpt.6100038 10.2165/00003088-199018050-00004 10.1007/BF00191898 10.2215/CJN.02920707 10.4065/83.9.1064 10.1016/j.ejphar.2008.02.085 10.1046/j.1471-4159.2002.01177.x 10.1093/ndt/gfh839 10.1016/S0006-2952(97)00534-0 10.1007/s10047-004-0257-9 10.1016/j.clinbiochem.2004.09.025 10.1146/annurev.pharmtox.44.101802.121856 10.1097/00000542-200210000-00011 10.2174/1389200033489532 10.1136/bmj.292.6535.1548 10.1016/0163-7258(91)90065-T 10.1038/sj.clpt.6100050 10.2165/00002018-200730110-00001 10.2165/00003088-197601050-00004 10.1097/00007691-200406000-00015 10.1056/NEJMra054415 10.1016/j.clpt.2005.10.005 10.2174/1389200033489389 10.1136/bmj.38476.471088.3A 10.2165/00003088-199631060-00002 10.1001/jama.298.17.2038 10.1111/j.1525-1594.1995.tb02272.x 10.2165/00003088-200342140-00002 10.1097/00000542-199409001-00086 10.1007/s00228-007-0329-x 10.1038/sj.bjp.0706138 10.2165/00003088-198106050-00001 10.1046/j.1365-2125.1999.00938.x 10.1007/s11095-007-9254-z 10.1016/j.clpt.2006.05.006 10.1097/MNH.0b013e3282fb77f2 10.1097/01.ftd.0000183384.89275.f4 10.2165/00003088-200847110-00001 10.1124/dmd.104.000521 10.1007/s002280050074 10.1016/j.pharmthera.2005.05.010 10.1093/bja/71.2.282 10.2165/00003088-200746080-00004 10.1046/j.1523-1755.2001.07831.x 10.1016/S0009-9236(03)00015-8 10.2165/00003088-200544040-00001 10.3109/03009748109095297 10.1681/ASN.2006060610 10.1097/00003246-199310000-00016 10.2165/00003088-200847090-00002 10.1007/BF00544072 10.1111/j.1365-2125.2007.02987.x 10.1111/j.1365-2125.2005.02393.x 10.1016/S0140-6736(84)90323-4 10.1038/sj.bjp.0704951 10.1124/dmd.105.006601 10.1038/clpt.2008.59 10.1159/000180580 10.1016/j.clpt.2005.02.012 10.1111/j.1600-0773.1988.tb00965.x 10.2215/CJN.01580407 10.2165/00003088-199732010-00002 10.1038/clpt.2008.208 10.1016/S0009-2797(03)00020-6 10.1007/s11095-004-9004-4 10.1038/sj.ki.5002634 10.1681/ASN.2006010035 10.1124/jpet.106.112631 10.1159/000189456 10.1038/sj.clpt.6100148 10.2174/138920006774832604 10.1046/j.0306-5251.2001.00029.x 10.1046/j.1365-2125.2001.01390.x 10.1124/dmd.107.018192 10.1097/01.ASN.0000017575.50319.77 10.1016/S0009-9236(03)00056-0 10.1046/j.1365-2125.1999.00046.x 10.1046/j.1471-4159.2003.01990.x 10.1097/00041552-199811000-00009 10.1152/ajprenal.00123.2002 10.1038/clpt.1990.203 10.1038/clpt.1986.151 10.1111/j.1365-2125.2007.03073.x 10.1182/blood.V94.8.2569.420k13_2569_2574 10.1038/clpt.1980.94 10.1007/s00228-008-0553-z 10.1681/ASN.V122326 10.1038/clpt.1992.47 10.1177/106002809202601116 10.1681/ASN.V891470 10.1097/00000542-199407000-00013 10.7326/0003-4819-130-6-199903160-00002 10.1177/039139880402700511 10.1254/jphs.08042FP 10.1111/j.1365-2125.2007.02963.x 10.1038/clpt.1993.127 10.1016/S0272-6386(86)80148-2 10.1111/j.1365-2125.1984.tb02451.x 10.5055/jom.2005.0021 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag 2009 2009 INIST-CNRS |
| Copyright_xml | – notice: Springer-Verlag 2009 – notice: 2009 INIST-CNRS |
| DBID | FBQ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7U9 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7S9 L.6 7X8 |
| DOI | 10.1007/s00228-009-0678-8 |
| DatabaseName | AGRIS CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Academic Middle East (New) AGRICOLA MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-1041 |
| EndPage | 773 |
| ExternalDocumentID | 1802740491 19543887 21752300 10_1007_s00228_009_0678_8 US201301658724 |
| Genre | Journal Article Review |
| GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3SX 3V. 4.4 406 408 409 40D 40E 476 53G 5QI 5RE 5VS 67N 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8FW 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AANXM AANZL AARHV AARTL AATNV AATVU AAUYE AAWCG AAWTL AAYFA AAYIU AAYOK AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABELW ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFO ACGFS ACHSB ACHVE ACHXU ACIGE ACIHN ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACREN ACTTH ACVWB ACWMK ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADMDM ADOAH ADOXG ADRFC ADTPH ADURQ ADYFF ADYOE ADYPR ADZKW AEAQA AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFDYV AFEXP AFFNX AFGCZ AFKRA AFLOW AFNRJ AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG AOSHJ ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECT EIHBH EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG EX3 F5P FBQ FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TSG TSK TSV TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 WOW Y6R YLTOR Z45 Z7U Z7V Z7W Z81 Z82 Z83 Z87 Z8O Z8P Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AACDK AAJBT AASML AAYZH ABAKF ABQSL ACAOD ACDTI ACPIV ACZOJ ADOJX AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU ALIPV BSONS H13 AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ IQODW PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7TK 7U9 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7S9 L.6 7X8 |
| ID | FETCH-LOGICAL-c479t-2e4056b9d4c355859ddbe6ac673dcc103c885565c4250c0b02c919d34c5811cc3 |
| IEDL.DBID | 7X7 |
| ISSN | 0031-6970 1432-1041 |
| IngestDate | Fri Jul 11 02:32:14 EDT 2025 Fri Jul 11 09:32:20 EDT 2025 Sat Aug 16 22:21:38 EDT 2025 Mon Jul 21 05:59:13 EDT 2025 Mon Jul 21 09:13:59 EDT 2025 Tue Jul 01 01:41:06 EDT 2025 Thu Apr 24 22:57:57 EDT 2025 Fri Feb 21 02:34:19 EST 2025 Wed Dec 27 19:09:03 EST 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Renal drug clearance Dosage adjustment Non-renal drug clearance Pharmacokinetic/pharmacodynamic processes Renal dysfunction Human Drug Pharmacodynamics Clearance Biological activity Kidney Urinary system Dysfunction Pharmacokinetics |
| Language | English |
| License | http://www.springer.com/tdm CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c479t-2e4056b9d4c355859ddbe6ac673dcc103c885565c4250c0b02c919d34c5811cc3 |
| Notes | http://dx.doi.org/10.1007/s00228-009-0678-8 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Review-3 |
| PMID | 19543887 |
| PQID | 214479001 |
| PQPubID | 47171 |
| PageCount | 17 |
| ParticipantIDs | proquest_miscellaneous_67516516 proquest_miscellaneous_46326660 proquest_journals_214479001 pubmed_primary_19543887 pascalfrancis_primary_21752300 crossref_primary_10_1007_s00228_009_0678_8 crossref_citationtrail_10_1007_s00228_009_0678_8 springer_journals_10_1007_s00228_009_0678_8 fao_agris_US201301658724 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2009-08-01 |
| PublicationDateYYYYMMDD | 2009-08-01 |
| PublicationDate_xml | – month: 08 year: 2009 text: 2009-08-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Heidelberg – name: Germany |
| PublicationTitle | European journal of clinical pharmacology |
| PublicationTitleAbbrev | Eur J Clin Pharmacol |
| PublicationTitleAlternate | Eur J Clin Pharmacol |
| PublicationYear | 2009 |
| Publisher | Berlin/Heidelberg : Springer-Verlag Springer-Verlag Springer Springer Nature B.V |
| Publisher_xml | – name: Berlin/Heidelberg : Springer-Verlag – name: Springer-Verlag – name: Springer – name: Springer Nature B.V |
| References | Leblond, Guévin, Demers, Pellerin, Gascon-Barré, Pichette (CR56) 2001; 12 Sanderink, Guimart, Ozoux, Jariwala, Shukla, Boutouyrie (CR118) 2002; 105 Dowling, Briglia, Fink, Hanes, Light, Stackiewicz, Karyekar, Eddington, Weir, Henrich (CR48) 2003; 73 Naud, Michaud, Leblond, Lefrancois, Bonnardeaux, Pichette (CR87) 2008; 36 Davies, Kingswood, Street (CR38) 1996; 31 Michaud, Naud, Chouinard, Désy, Leblond, Desbiens, Bonnardeaux, Pichette (CR63) 2006; 17 Gjessing (CR106) 2008; 108 Levey, Greene, Kusk, Beck (CR10) 2000; 11 Lee, Kim (CR24) 2004; 44 Osborne, Joel, Slevin (CR94) 1986; 292 Periclou, Ventura, Niranjan, Abramowitz (CR44) 2006; 79 Niwa, Miyazaki, Katsuzaki, Tatemichi, Takei (CR88) 1996; 74 Decker, Mueller, Sowinski (CR114) 2007; 14 Gross, MacLachlan, Minns (CR22) 2001; 51 Lam, Okochi, Huanh, Benet (CR84) 2006; 34 Gusella, Rebeschini, Cartel, Ferrazzi, Ferrari, Padrini (CR90) 2005; 27 Kays, Overholser, Mueller (CR40) 2003; 42 Lam, Banerji, Hatfield, Talbert (CR33) 1997; 32 Benet, Cummins, Wu (CR82) 2003; 4 Sun, Frassetto, Benet (CR62) 2006; 109 Coresh, Selvin, Stevens (CR2) 2007; 298 Säwe, Odar-Cederlöf (CR95) 1987; 32 Matzke, Comstock, Burton, Shaw, Schentag, Evans (CR34) 2006 Committee (CR135) 2004 Gaspari, Perico, Remuzzi (CR7) 1998; 7 Sica (CR20) 2007; 46 Mazoit, Sandouk, Scherrmann, Roche (CR77) 1990; 48 Levey, Bosch, Lewis, Greene, Rogers, Roth (CR9) 1999; 130 How, Fischer, Arruda (CR41) 2007; 2 Leblond, Petrucci, Dubé, Bernier, Bonnardeaux, Pichette (CR57) 2002; 13 Tett, Kirkpatrick, Gross, McLachlan (CR5) 2003; 42 Fuhr, Jetter, Kirchheiner (CR21) 2007; 81 Teunissen, Kampf, Roots (CR54) 1985; 28 Elston, Bayliss, Park (CR47) 1993; 71 Yu, Ritter, Krieg, Rege, Karnes, Sarkar (CR66) 2006; 34 Hulot, Montalescot, Lechat, Collet, Ankri, Urien (CR133) 2005; 77 Michaud, Nolin, Naud, Dani, Lafrance, Leblond, Himmelfarb, Pichette (CR91) 2008; 108 Stevens, Coresh, Greene, Levey (CR4) 2006; 354 Koepell, Lips, Volk (CR26) 2007; 24 CR137 Balant, Dayer, Fabre (CR45) 1983; 3 CR138 Aronson (CR14) 2007; 63 Daniel, Rubio-Aliaga (CR30) 2003; 284 CR136 Golper, Marx, Shuler, Jacobs, Kjellstrand, Koch (CR111) 1996 Raoof, Van Obbergh, de Ville de Goyet, Verbeeck (CR75) 1996; 50 CR132 Herget-Rosenthal, Bökenkamp, Hofmann (CR15) 2007; 40 Sun, Huang, Frassetto, Benet (CR60) 2004; 32 Verbeeck (CR53) 2008; 64 Brater, Anderson, Brown-Cartwright (CR117) 1986; 40 Fischer (CR121) 2007; 11 Dreisbach, Japa, Gebrekal, Mowry, Lertora, Kamath, Rettie (CR50) 2003; 73 Lau, Huang, Frassetto, Benet (CR85) 2007; 81 McQuay, Moore (CR93) 1984; ii Hiraoka, Yamamoto, Miyoshi, Morita, Nakamura, Kadoi, Kunimoto, Horiuchi (CR79) 2005; 60 Proulx, Akbari, Garg, Rostom, Jaffey, Clark (CR18) 2005; 20 Levy, Giacomini, Prescott, Nimmo (CR36) 1981 Brophy, Sica (CR122) 2007; 30 Muirhead, Wilner, Colburn, Haug-Pihale, Rouvieux (CR39) 2002; 53 Cockroft, Gault (CR8) 1976; 16 Fareed, Hoppensteadt, Walnga, Iqbal, Ma, Jeske, Sheikh (CR123) 2003; 42 Stehle, Kirchheiner, Lazar, Fuhr (CR51) 2008; 47 Vree, Hekster, Anderson (CR78) 1992; 26 Gibson, Giacomini, Briggs (CR35) 1980; 27 Nolin, Appiah, Kendrick, Le, McMonagle, Himmelfarb (CR67) 2006; 17 Peck, Barr, Benet (CR126) 1992; 51 Guévin, Michaud, Naud, Leblond, Pichette (CR58) 2002; 137 Noris, Remuzzi (CR120) 1999; 94 Wilkinson (CR27) 1987; 39 Bianchetti, Graziani, Brancacci (CR37) 1976; 1 Toublanc, Sargentini-Maier, Lacroix, Jacqmin, Stockis (CR129) 2008; 47 Rowland, Tozer (CR32) 1995 Bricker, Morrin, Kime (CR43) 1997; 8 Yue, Odar-Cederlöf, Svensson, Säwe (CR74) 1988; 63 CR112 Robert, Zarowitz, Peterson, Dumler (CR12) 1993; 21 CR110 (CR139) 2005; 331 Lötsch, Schmidt, Vetter, Schmidt, Niederberger, Geisslinger, Tegeder (CR102) 2002; 83 Frye (CR52) 2006; 80 Verpooten, Verbist, Buntinx, Entwistle, Jones, De Broe (CR80) 1984; 18 Lötsch, Zimmermann, Darimont, Marx, Dudziak, Skarke, Geisslinger (CR104) 2002; 97 Aarons, Balant, Mentré (CR127) 1994; 46 Miners, Mackenzie (CR68) 1991; 51 McGurk, Brierley, Burchell (CR76) 1998; 55 Hulot, Vantelon, Urien, Bouzamondo, Mahé, Ankri, Montalescot, Lechat (CR119) 2004; 26 Penson, Joel, Gloyne, Clark, Slevin (CR99) 2005; 1 Naud, Michaud, Boisvert, Desbiens, Leblod, Mitchell, Jones, Bonnardeaux, Pichette (CR86) 2007; 320 Sowinski, Magner, Lucksiri, Scott, Hamburger, Mueller (CR115) 2008; 3 Nolin, Naud, Leblond, Pichette (CR64) 2008; 83 Skeith, Dasgupta, Lange, Jamali (CR72) 1996; 42 Pasternak, Bodnar, Clark, Interrusi (CR97) 1987; 41 Woffindin, Hoenich (CR105) 1995; 19 Zhang, Zhang, Abraham, Apparaju, Wu, Strong, Xiao, Atkinson, Thummel, Leeder, Lee, Burckart, Lesko, Huang (CR125) 2009; 85 Mahmood, Green (CR29) 2005; 44 Graves (CR3) 2008; 83 Osborne, Joel, Grebenik, Trew, Slevin (CR96) 1993; 54 Verbeeck, Branch, Wilkinson (CR92) 1981; 6 de Jong, Gansevoort (CR6) 2008; 23 CR128 Stafanger, Larson, Hansen, Sorensen (CR71) 1981; 10 Wu, Benet (CR83) 2005; 22 Lucchi, Fiore, Guadagni, Perrone, Malaguti, Caruso, Fumero, Albertazzi (CR108) 2004; 27 Work, Schwartz (CR17) 2008; 17 Penson, Joel, Bakhshi, Clark, Langford, Slevin (CR98) 2000; 68 MacKichan, Burton, Shaw, Schentag, Evans (CR42) 2006 Vidal, Shavit, Fraser, Paul, Leibovici (CR134) 2005; 331 Dale, Thoner, Nilsen, Tveita, Borchgrevink, Klepstad (CR100) 2007; 63 Braeckman, Reid (CR31) 2000 Gibson (CR46) 1986; 8 Tzeng, Schneck, Birmingham, Mitchell, Zhang, Martin, Kung (CR131) 2008; 24 Simard, Naud, Michaud, Leblond, Bonnardeaux, Guillemette, Sim, Pichette (CR65) 2008; 19 Edholm, Berglund, Salmonson (CR124) 2008; 48 Dzurik, Spustova, Krivosikova, Gazdikova (CR89) 2001; 78 Frassetto, Poon, Tsourounis, Valera, Benet (CR49) 2007; 81 Grubb, Rudy, Brater, Hall (CR73) 1999; 48 Thummel, Shen, Isoherranen, Smith, Brunton, Lazo, Parker (CR1) 2006 Ponto, Schoenwald (CR116) 1990; 18 Pichette, Leblond (CR59) 2003; 4 Bourasset, Cisternino, Temsamani, Scherrmann (CR103) 2003; 86 Asari, Iles-Smith, Chen, Naderer, Johnson, Yuen, Otto, Dunn, Gokal (CR113) 2007; 64 Verbeeck (CR70) 1982; 10 Bostom, Kronenberg, Eberhard (CR11) 2002; 13 Bailey, Dickinson (CR69) 2003; 145 Waller (CR19) 2007; 64 Filler, Bökenkamp, Hofmann, Lebricon, Martinez-Bru, Grubb (CR16) 2005; 38 Baumann (CR28) 2006; 7 CR23 D’Honneur, Gilton, Sandouk, Scherrmann, Duvaldestin (CR101) 1994; 81 El-Sheikh, Masereeuw, Russel (CR25) 2008; 585 Leblond, Giroux, Villeneuve, Pichette (CR55) 2000; 28 Kirkpatrick, Duffull, Begg (CR13) 1999; 47 Michaud, Dubé, Naud, Leblond, Desbiens, Bonnardeaux, Pichette (CR61) 2005; 144 Ho, Kim (CR81) 2005; 78 Fujimura, Uchi, Fukuda, Miyazaki, Uezumi, Hiyoshi (CR107) 2004; 7 CR109 Zandvliet, Schellens, Beijnen, Huitema (CR130) 2008; 47 A Fuhr (678_CR21) 2007; 81 T Fujimura (678_CR107) 2004; 7 DA Sica (678_CR20) 2007; 46 KA McGurk (678_CR76) 1998; 55 Y Zhang (678_CR125) 2009; 85 R Dzurik (678_CR89) 2001; 78 NS Bricker (678_CR43) 1997; 8 DC Brater (678_CR117) 1986; 40 J Fareed (678_CR123) 2003; 42 CM Kirkpatrick (678_CR13) 1999; 47 J Michaud (678_CR63) 2006; 17 G Bianchetti (678_CR37) 1976; 1 J Lötsch (678_CR102) 2002; 83 NL Proulx (678_CR18) 2005; 20 M Gusella (678_CR90) 2005; 27 J Coresh (678_CR2) 2007; 298 KE Thummel (678_CR1) 2006 TA Golper (678_CR111) 1996 J Naud (678_CR86) 2007; 320 678_CR53 J-S Hulot (678_CR133) 2005; 77 LA Stevens (678_CR4) 2006; 354 YY Lau (678_CR85) 2007; 81 J Lötsch (678_CR104) 2002; 97 RT Penson (678_CR99) 2005; 1 MJ Bailey (678_CR69) 2003; 145 TD Nolin (678_CR67) 2006; 17 PE Jong de (678_CR6) 2008; 23 S Stehle (678_CR51) 2008; 47 N Toublanc (678_CR129) 2008; 47 TD Nolin (678_CR64) 2008; 83 J Säwe (678_CR95) 1987; 32 GJ Sanderink (678_CR118) 2002; 105 TP Gibson (678_CR46) 1986; 8 H McQuay (678_CR93) 1984; ii GJ Muirhead (678_CR39) 2002; 53 JW Graves (678_CR3) 2008; 83 H Hiraoka (678_CR79) 2005; 60 678_CR23 L Lucchi (678_CR108) 2004; 27 C Guévin (678_CR58) 2002; 137 JF Committee (678_CR135) 2004 KM Sowinski (678_CR115) 2008; 3 JS Hulot (678_CR119) 2004; 26 AS Zandvliet (678_CR130) 2008; 47 V Pichette (678_CR59) 2003; 4 FA Leblond (678_CR57) 2002; 13 JX Mazoit (678_CR77) 1990; 48 FA Leblond (678_CR55) 2000; 28 L Aarons (678_CR127) 1994; 46 R Braeckman (678_CR31) 2000 A Periclou (678_CR44) 2006; 79 CY Wu (678_CR83) 2005; 22 AS Gross (678_CR22) 2001; 51 AAK El-Sheikh (678_CR25) 2008; 585 MB Kays (678_CR40) 2003; 42 JL Lam (678_CR84) 2006; 34 M Rowland (678_CR32) 1995 M Edholm (678_CR124) 2008; 48 RK Verbeeck (678_CR70) 1982; 10 DF Work (678_CR17) 2008; 17 JJ MacKichan (678_CR42) 2006 YWF Lam (678_CR33) 1997; 32 GW Pasternak (678_CR97) 1987; 41 H Koepell (678_CR26) 2007; 24 RK Verbeeck (678_CR92) 1981; 6 NG Grubb (678_CR73) 1999; 48 AA Raoof (678_CR75) 1996; 50 A Baumann (678_CR28) 2006; 7 W Lee (678_CR24) 2004; 44 678_CR112 678_CR110 Letters to the Editor (678_CR139) 2005; 331 TC Dowling (678_CR48) 2003; 73 GR Matzke (678_CR34) 2006 J Michaud (678_CR61) 2005; 144 F Gaspari (678_CR7) 1998; 7 TP Gibson (678_CR35) 1980; 27 DF Brophy (678_CR122) 2007; 30 LL Ponto (678_CR116) 1990; 18 TB Vree (678_CR78) 1992; 26 QY Yue (678_CR74) 1988; 63 C Peck (678_CR126) 1992; 51 678_CR109 AC Elston (678_CR47) 1993; 71 LA Frassetto (678_CR49) 2007; 81 C Woffindin (678_CR105) 1995; 19 AS Levey (678_CR10) 2000; 11 T Niwa (678_CR88) 1996; 74 JO Miners (678_CR68) 1991; 51 G Davies (678_CR38) 1996; 31 KJ Skeith (678_CR72) 1996; 42 SE Tett (678_CR5) 2003; 42 RT Penson (678_CR98) 2000; 68 F Bourasset (678_CR103) 2003; 86 678_CR91 JK Aronson (678_CR14) 2007; 63 PP How (678_CR41) 2007; 2 G Filler (678_CR16) 2005; 38 LP Balant (678_CR45) 1983; 3 AW Dreisbach (678_CR50) 2003; 73 H Sun (678_CR60) 2004; 32 M Noris (678_CR120) 1999; 94 KG Fischer (678_CR121) 2007; 11 MWE Teunissen (678_CR54) 1985; 28 678_CR138 LZ Benet (678_CR82) 2003; 4 678_CR137 GR Wilkinson (678_CR27) 1987; 39 678_CR136 GA Verpooten (678_CR80) 1984; 18 E Simard (678_CR65) 2008; 19 678_CR132 F Leblond (678_CR56) 2001; 12 R Osborne (678_CR94) 1986; 292 G Stafanger (678_CR71) 1981; 10 J Gjessing (678_CR106) 2008; 108 S Robert (678_CR12) 1993; 21 BS Decker (678_CR114) 2007; 14 A Asari (678_CR113) 2007; 64 H Sun (678_CR62) 2006; 109 S Herget-Rosenthal (678_CR15) 2007; 40 G D’Honneur (678_CR101) 1994; 81 G Levy (678_CR36) 1981 J Naud (678_CR87) 2008; 36 678_CR128 TB Tzeng (678_CR131) 2008; 24 RH Ho (678_CR81) 2005; 78 RF Frye (678_CR52) 2006; 80 H Daniel (678_CR30) 2003; 284 R Osborne (678_CR96) 1993; 54 O Dale (678_CR100) 2007; 63 DG Waller (678_CR19) 2007; 64 L Vidal (678_CR134) 2005; 331 AS Levey (678_CR9) 1999; 130 C Yu (678_CR66) 2006; 34 AG Bostom (678_CR11) 2002; 13 I Mahmood (678_CR29) 2005; 44 DW Cockroft (678_CR8) 1976; 16 6147317 - Int J Clin Pharmacol Res. 1983;3(6):459-74 16153397 - Clin Pharmacol Ther. 2005 Sep;78(3):260-77 8354025 - Clin Pharmacol Ther. 1993 Aug;54(2):158-67 11422014 - Br J Clin Pharmacol. 2001 Jun;51(6):547-55 15607309 - Clin Biochem. 2005 Jan;38(1):1-8 12138147 - J Am Soc Nephrol. 2002 Aug;13(8):2140-4 12423235 - J Neurochem. 2002 Oct;83(2):241-8 6124391 - Drug Metab Dispos. 1982 Jan-Feb;10(1):87-9 14744242 - Annu Rev Pharmacol Toxicol. 2004;44:137-66 16413248 - Clin Pharmacol Ther. 2006 Jan;79(1):134-43 17135344 - J Pharmacol Exp Ther. 2007 Mar;320(3):978-85 8579523 - Artif Organs. 1995 Nov;19(11):1113-9 18399714 - Clin Pharmacokinet. 2008;47(5):333-41 16042671 - Br J Clin Pharmacol. 2005 Aug;60(2):176-82 12686489 - Chem Biol Interact. 2003 May 6;145(2):117-37 8938685 - Nephron. 1996;74(3):580-5 2249372 - Clin Pharmacol Ther. 1990 Dec;48(6):613-8 9012555 - Clin Pharmacokinet. 1997 Jan;32(1):30-57 17259951 - Clin Pharmacol Ther. 2007 Feb;81(2):270-83 17403168 - Hemodial Int. 2007 Apr;11(2):178-89 11879256 - Br J Clin Pharmacol. 2002;53 Suppl 1:21S-30S 18359868 - Nephrol Dial Transplant. 2008 Apr;23(4):1092-5 4043202 - Eur J Clin Pharmacol. 1985;28(5):589-95 9605424 - Biochem Pharmacol. 1998 Apr 1;55(7):1005-12 10583018 - Br J Clin Pharmacol. 1999 Oct;48(4):494-500 8864313 - Br J Clin Pharmacol. 1996 Aug;42(2):163-9 18408486 - Curr Opin Nephrol Hypertens. 2008 May;17(3):320-5 17603971 - Adv Chronic Kidney Dis. 2007 Jul;14(3):e17-26 18417112 - Eur J Pharmacol. 2008 May 13;585(2-3):245-55 6146831 - Lancet. 1984 Aug 4;2(8397):284-5 15202820 - Int J Artif Organs. 2004 May;27(5):414-9 2185908 - Clin Pharmacokinet. 1990 May;18(5):381-408 16085315 - Pharmacol Ther. 2006 Jan;109(1-2):1-11 17940133 - Drug Metab Dispos. 2008 Jan;36(1):124-8 18698879 - Clin Pharmacokinet. 2008;47(9):565-94 7037261 - Clin Pharmacokinet. 1981 Sep-Oct;6(5):329-45 14606929 - Clin Pharmacokinet. 2003;42(14):1193-211 17361125 - Clin Pharmacol Ther. 2007 Jun;81(6):828-32 17986697 - JAMA. 2007 Nov 7;298(17):2038-47 10515859 - Blood. 1999 Oct 15;94(8):2569-74 8739817 - Eur J Clin Pharmacol. 1996;50(1-2):91-6 18417721 - J Am Soc Nephrol. 2008 Jul;19(7):1352-9 12732843 - Clin Pharmacol Ther. 2003 May;73(5):427-34 17473959 - Pharm Res. 2007 Jul;24(7):1227-51 15700027 - Br J Pharmacol. 2005 Apr;144(8):1067-77 11927128 - Thromb Res. 2002 Feb 1;105(3):225-31 11169026 - Kidney Int Suppl. 2001 Feb;78:S278-81 17913970 - Clin J Am Soc Nephrol. 2007 Nov;2(6):1235-40 3524205 - Am J Kidney Dis. 1986 Jul;8(1):7-17 11180027 - Clin Pharmacol Ther. 2000 Dec;68(6):667-76 12678690 - Curr Drug Metab. 2003 Apr;4(2):91-103 17973538 - Drug Saf. 2007;30(11):991-4 14655198 - Am J Kidney Dis. 2003 Dec;42(6):1253-9 7957530 - Eur J Clin Pharmacol. 1994;46(5):389-91 18388866 - Clin Pharmacol Ther. 2008 Jun;83(6):898-903 19020495 - Clin Pharmacol Ther. 2009 Mar;85(3):305-11 11038159 - Drug Metab Dispos. 2000 Nov;28(11):1317-20 12039987 - J Am Soc Nephrol. 2002 Jun;13(6):1579-85 17021269 - J Am Soc Nephrol. 2006 Nov;17(11):3041-8 18840025 - Clin Pharmacokinet. 2008;47(11):693-701 1792239 - Pharmacol Ther. 1991;51(3):347-69 15855207 - Nephrol Dial Transplant. 2005 Aug;20(8):1617-22 7371364 - Clin Pharmacol Ther. 1980 May;27(5):665-70 9294841 - J Am Soc Nephrol. 1997 Sep;8(9):1470-6 10383541 - Br J Clin Pharmacol. 1999 Jun;47(6):637-43 3609116 - Eur J Clin Pharmacol. 1987;32(4):377-82 16760447 - N Engl J Med. 2006 Jun 8;354(23):2473-83 12959635 - Clin Pharmacokinet. 2003;42(12):1043-57 12732848 - Clin Pharmacol Ther. 2003 May;73(5):475-7 18379543 - Kidney Int Suppl. 2008 Apr;(108):S18-25 15905228 - BMJ. 2005 Jul 30;331(7511):263 16306860 - Ther Drug Monit. 2005 Dec;27(6):816-8 18762933 - Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61 17192770 - Clin Pharmacol Ther. 2007 Feb;81(2):194-204 17234172 - Clin Biochem. 2007 Feb;40(3-4):153-61 6593092 - Br J Clin Pharmacol. 1984 Aug;18(2):183-93 17619868 - Eur J Clin Pharmacol. 2007 Sep;63(9):837-42 1244564 - Nephron. 1976;16(1):31-41 18775206 - Mayo Clin Proc. 2008 Sep;83(9):1064-9 3731676 - Clin Pharmacol Ther. 1986 Aug;40(2):134-9 15558337 - J Artif Organs. 2004;7(3):149-54 16698890 - Drug Metab Dispos. 2006 Aug;34(8):1336-44 15771225 - Pharm Res. 2005 Jan;22(1):11-23 1017154 - Clin Pharmacokinet. 1976;1(5):373-84 18845914 - J Pharmacol Sci. 2008 Oct;108(2):157-63 8968655 - Clin Pharmacokinet. 1996 Dec;31(6):410-22 16454690 - Curr Drug Metab. 2006 Jan;7(1):15-21 11158222 - J Am Soc Nephrol. 2001 Feb;12(2):326-32 16415115 - Drug Metab Dispos. 2006 Apr;34(4):621-7 17319252 - J Opioid Manag. 2005 May-Jun;1(2):83-90 12676733 - Am J Physiol Renal Physiol. 2003 May;284(5):F885-92 2826951 - Life Sci. 1987 Dec 28;41(26):2845-9 18611060 - Clin Pharmacokinet. 2008;47(8):487-513 18674408 - Curr Med Res Opin. 2008 Sep;24(9):2575-85 17655374 - Clin Pharmacokinet. 2007;46(8):677-9 12429576 - Br J Pharmacol. 2002 Dec;137(7):1039-46 17662093 - Br J Clin Pharmacol. 2007 Dec;64(6):738-44 3554275 - Pharmacol Rev. 1987 Mar;39(1):1-47 10075613 - Ann Intern Med. 1999 Mar 16;130(6):461-70 12357145 - Anesthesiology. 2002 Oct;97(4):814-9 3087512 - Br Med J (Clin Res Ed). 1986 Jun 14;292(6535):1548-9 1563216 - Clin Pharmacol Ther. 1992 Apr;51(4):465-73 12950465 - J Neurochem. 2003 Sep;86(6):1564-7 1477449 - Ann Pharmacother. 1992 Nov;26(11):1421-8 15961985 - Clin Pharmacol Ther. 2005 Jun;77(6):542-52 8403957 - Crit Care Med. 1993 Oct;21(10):1487-95 18078474 - Br J Clin Pharmacol. 2007 Dec;64(6):719-21 15828849 - Clin Pharmacokinet. 2005;44(4):331-47 8042814 - Anesthesiology. 1994 Jul;81(1):87-93 9864664 - Curr Opin Nephrol Hypertens. 1998 Nov;7(6):675-80 14529371 - Curr Drug Metab. 2003 Oct;4(5):393-8 8123408 - Br J Anaesth. 1993 Aug;71(2):282-90 16899515 - J Am Soc Nephrol. 2006 Sep;17(9):2363-7 18235142 - Clin J Am Soc Nephrol. 2008 Mar;3(2):355-61 15286055 - Drug Metab Dispos. 2004 Nov;32(11):1239-46 16952490 - Clin Pharmacol Ther. 2006 Sep;80(3):235-45 7291952 - Scand J Rheumatol. 1981;10(3):189-92 3148914 - Pharmacol Toxicol. 1988 Nov;63(5):337-41 17488361 - Br J Clin Pharmacol. 2007 May;63(5):509-11 15167633 - Ther Drug Monit. 2004 Jun;26(3):305-10 |
| References_xml | – start-page: 115 year: 1981 end-page: 122 ident: CR36 article-title: First-pass effects in health and disease: pharmacokinetics studies on dextropropoxyphene publication-title: Drug absorption—Proc Edinburgh Int Conf – volume: 105 start-page: 225 year: 2002 end-page: 231 ident: CR118 article-title: Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment publication-title: Thromb Res doi: 10.1016/S0049-3848(02)00031-2 – volume: 24 start-page: 2575 year: 2008 end-page: 2585 ident: CR131 article-title: Population pharmacokinetics of rosuvastatin: implications of renal impairment, race and dyslipidaemias publication-title: Curr Med Res Opin doi: 10.1185/03007990802312807 – volume: 32 start-page: 377 year: 1987 end-page: 382 ident: CR95 article-title: Kinetics of morphine in patients with renal failure publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00543973 – volume: 42 start-page: 163 year: 1996 end-page: 169 ident: CR72 article-title: The influence of renal function on the pharmacokinetics of unchanged and acyl- glucuronide ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1996.03864.x – volume: 40 start-page: 153 year: 2007 end-page: 161 ident: CR15 article-title: How to estimate GFR—serum creatinine, serum cystatin C or equations? publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2006.10.014 – volume: 68 start-page: 667 year: 2000 end-page: 676 ident: CR98 article-title: Randomized placebo-controlled trial of activity of the morphine glucuronides publication-title: Clin Pharmacol Ther doi: 10.1067/mcp.2000.111934 – volume: 47 start-page: 333 year: 2008 end-page: 341 ident: CR129 article-title: Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200847050-00004 – volume: 42 start-page: 1043 year: 2003 end-page: 1057 ident: CR123 article-title: Pharmacodynamic and harmacokinetic properties of enoxaparin: implications for clinical practice publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200342120-00003 – start-page: 750 year: 1996 end-page: 614 ident: CR111 article-title: Drug dosage in dialysis patients publication-title: Replacement of Renal Function by Dialysis doi: 10.1007/978-0-585-36947-1_30 – volume: 48 start-page: 613 year: 1990 end-page: 618 ident: CR77 article-title: Extrahepatic metabolism of morphine occurs in humans publication-title: Clin Pharmacol Ther – year: 1995 ident: CR32 publication-title: Clinical pharmacokinetics: concepts and applications – ident: CR138 – volume: 34 start-page: 1336 year: 2006 end-page: 1344 ident: CR84 article-title: In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism characterizing the importance of transporter-enzyme interplay publication-title: Drug Metab Disp doi: 10.1124/dmd.106.009258 – volume: 13 start-page: 2140 year: 2002 end-page: 2144 ident: CR11 article-title: Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000022011.35035.F3 – volume: 11 start-page: 178 year: 2007 end-page: 189 ident: CR121 article-title: Essentials of anticoagulation in hemodialysis publication-title: Hemodial Int doi: 10.1111/j.1542-4758.2007.00166.x – volume: 47 start-page: 487 year: 2008 end-page: 513 ident: CR130 article-title: Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200847080-00001 – volume: 41 start-page: 2845 year: 1987 end-page: 2849 ident: CR97 article-title: Morphine-6-glucuronide, a potent mu agonist publication-title: Life Sci doi: 10.1016/0024-3205(87)90431-0 – volume: 19 start-page: 1352 year: 2008 end-page: 1359 ident: CR65 article-title: Downregulation of hepatic acetylation of drugs in chronic renal failure publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2007090974 – volume: 14 start-page: 17 year: 2007 end-page: 26 ident: CR114 article-title: Drug dosing considerations in alternative hemodialysis publication-title: Adv Chronic Kidney Dis doi: 10.1053/j.ackd.2007.03.004 – start-page: 187 year: 2006 end-page: 212 ident: CR34 article-title: Influence of renal function and dialysis on drug disposition publication-title: Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring – volume: 28 start-page: 1317 year: 2000 end-page: 1320 ident: CR55 article-title: Decreased in vivo metabolism of drugs in chronic renal failure publication-title: Drug Metab Disp – volume: 63 start-page: 509 year: 2007 end-page: 511 ident: CR14 article-title: Drug therapy in kidney diesease publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2007.02917.x – volume: 23 start-page: 1092 year: 2008 end-page: 1095 ident: CR6 article-title: Fact or fiction of the epidemic of chronic kidney disease—let us not squabble about estimated GFR only, but also focus on albuminuria publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfn028 – ident: CR132 – volume: 40 start-page: 134 year: 1986 end-page: 139 ident: CR117 article-title: Response to furosemide in chronic renal insufficiency: rationale for limited doses publication-title: Clin Pharmacol Ther – volume: 108 start-page: 157 issue: 2 year: 2008 end-page: 163 ident: CR91 article-title: Effect of hemodialysis on hepatic Cytochrome P450 functional expression publication-title: J Pharmacol Sci – volume: 42 start-page: 1253 year: 2003 end-page: 1259 ident: CR40 article-title: Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2003.08.027 – volume: 78 start-page: 260 year: 2005 end-page: 277 ident: CR81 article-title: Transporters and drug therapy: implications for drug disposition and disease publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.05.011 – volume: 81 start-page: 194 year: 2007 end-page: 204 ident: CR85 article-title: Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100038 – volume: 18 start-page: 381 year: 1990 end-page: 408 ident: CR116 article-title: Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review (part I) publication-title: Clin Pharmacokinet doi: 10.2165/00003088-199018050-00004 – volume: 39 start-page: 1 year: 1987 end-page: 47 ident: CR27 article-title: Clearance approaches in pharmacology publication-title: Pharmacol Rev – volume: 18 start-page: 183 year: 1984 end-page: 193 ident: CR80 article-title: The pharmacokinetics of imipenem (thienamycin- formamidine) and the renal dehydropeptidase inhibitor cilastin sodium in normal subjects and patients with renal failure publication-title: Br J Clin Pharmacol – ident: CR112 – volume: 46 start-page: 389 year: 1994 end-page: 391 ident: CR127 article-title: Population approaches in drug development: report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00191898 – volume: 12 start-page: 326 year: 2001 end-page: 332 ident: CR56 article-title: Downregulation of hepatic cytochrome P450 in chronic renal failure publication-title: J Am Soc Nephrol – ident: CR109 – volume: 3 start-page: 355 year: 2008 end-page: 361 ident: CR115 article-title: Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.02920707 – volume: 83 start-page: 1064 year: 2008 end-page: 1069 ident: CR3 article-title: Diagnosis and management of chronic kidney disease publication-title: Mayo Clin Proc doi: 10.4065/83.9.1064 – volume: 585 start-page: 245 year: 2008 end-page: 255 ident: CR25 article-title: Mechanisms of renal anionic transport publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2008.02.085 – volume: 1 start-page: 83 year: 2005 end-page: 90 ident: CR99 article-title: Morphine analgesia in cancer pain: role of the glucuronides publication-title: J Opioid Manag – volume: 64 start-page: 738 year: 2007 end-page: 744 ident: CR113 article-title: Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure publication-title: Br J Clin Pharmacol – start-page: 1787 year: 2006 end-page: 1888 ident: CR1 article-title: Design and optimization of dosage regimens: pharmacokinetic data publication-title: Goodman & Gilman’s The Pharmacological Basis of Therapeutics – volume: 83 start-page: 241 year: 2002 end-page: 248 ident: CR102 article-title: Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein publication-title: J Neurochem doi: 10.1046/j.1471-4159.2002.01177.x – volume: 20 start-page: 1617 year: 2005 end-page: 1622 ident: CR18 article-title: Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfh839 – volume: 55 start-page: 1005 year: 1998 end-page: 1012 ident: CR76 article-title: Drug glucuronidation by human reanl UDP-glucuronosyltransferases publication-title: Biochem Pharmacol doi: 10.1016/S0006-2952(97)00534-0 – volume: 7 start-page: 149 year: 2004 end-page: 153 ident: CR107 article-title: Development of a dialyzer with enhanced internal filtration to increase the clearance of low molecular weight proteins publication-title: J Artif Organs doi: 10.1007/s10047-004-0257-9 – volume: 38 start-page: 1 year: 2005 end-page: 8 ident: CR16 article-title: Cystatin C as a marker of GFR—history, indications, and future research publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2004.09.025 – volume: 44 start-page: 137 year: 2004 end-page: 166 ident: CR24 article-title: Transporters and renal elimination publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev.pharmtox.44.101802.121856 – volume: 97 start-page: 814 year: 2002 end-page: 819 ident: CR104 article-title: Does the A118G polymorphism at the µ-opioid receptor gene protect against morphine-6-glucuronide toxicity? publication-title: Anesthesiology doi: 10.1097/00000542-200210000-00011 – volume: 4 start-page: 91 year: 2003 end-page: 103 ident: CR59 article-title: Drug metabolism in chronic renal failure publication-title: Curr Drug Metab doi: 10.2174/1389200033489532 – volume: 292 start-page: 1548 year: 1986 end-page: 1549 ident: CR94 article-title: Morphine intoxication in renal insufficiency: the role of morphine-6-glucuronide publication-title: Br Med J doi: 10.1136/bmj.292.6535.1548 – volume: 51 start-page: 347 year: 1991 end-page: 369 ident: CR68 article-title: Drug glucuronidation in humans publication-title: Pharmacol Ther doi: 10.1016/0163-7258(91)90065-T – ident: CR137 – volume: 81 start-page: 270 year: 2007 end-page: 283 ident: CR21 article-title: Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the „cocktail“ approach publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100050 – volume: 8 start-page: 7 year: 1986 end-page: 17 ident: CR46 article-title: Renal disease and drug metabolism publication-title: Am J Kidney Dis – start-page: 82 year: 2006 end-page: 120 ident: CR42 article-title: Influence of protein binding and use of unbound (free) drug concentrations publication-title: Applied pharmacokinetics and pharmacodynamics—principles of therapeutic drug monitoring – volume: 3 start-page: 459 year: 1983 end-page: 474 ident: CR45 article-title: Consequences of renal insufficiency on the hepatic clearance of some drugs publication-title: Int J Clin Pharmacol Res – volume: 27 start-page: 414 year: 2004 end-page: 419 ident: CR108 article-title: Clinical evaluation of internal hemodiafiltration (iHDF): a diffusive-convective technique performed with internal filtration enhanced high-fluc dialyzers publication-title: Int J Artif Organs – volume: 30 start-page: 991 year: 2007 end-page: 994 ident: CR122 article-title: Use of enoxaparin in patients with chronic kidney disease: safety considerations publication-title: Drug Saf doi: 10.2165/00002018-200730110-00001 – volume: 1 start-page: 373 year: 1976 end-page: 384 ident: CR37 article-title: Pharmacokinetics and effects of propranolol in terminal uremic patients and in patients undergoing regular dialysis treatment publication-title: Clin Pharmacokinet doi: 10.2165/00003088-197601050-00004 – volume: 94 start-page: 2569 year: 1999 end-page: 2574 ident: CR120 article-title: Uremic bleeding: closing the circle after 30 years of controversies? publication-title: Blood – volume: 51 start-page: 465 year: 1992 end-page: 473 ident: CR126 article-title: Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development publication-title: Clin Pharmacol Ther – volume: 284 start-page: F885 year: 2003 end-page: F892 ident: CR30 article-title: An update on renal peptide transporters publication-title: Am J Renal Physiol – volume: 7 start-page: 675 year: 1998 end-page: 680 ident: CR7 article-title: Application of newer clearance techniques for the determination of glomerular filtration rate publication-title: Curr Opin Nephrol Hypertens – volume: 331 start-page: 292 year: 2005 end-page: 294 ident: CR139 article-title: Dose adjustment in renal impairment publication-title: Br Med J – volume: 26 start-page: 305 year: 2004 end-page: 310 ident: CR119 article-title: Effect of renal failure on the pharmacokinetics of enoxaparin and consequences on dose adjustment publication-title: Ther Drug Monit doi: 10.1097/00007691-200406000-00015 – volume: 354 start-page: 2473 year: 2006 end-page: 2483 ident: CR4 article-title: Assessing kidney function—measured and estimated glomerular filtration rate publication-title: N Engl J Med doi: 10.1056/NEJMra054415 – volume: 54 start-page: 158 year: 1993 end-page: 167 ident: CR96 article-title: The pharmacokinetics of morphine and morphine glucuronides in kidney failure publication-title: Clin Pharmacol Ther – volume: 79 start-page: 134 year: 2006 end-page: 143 ident: CR44 article-title: Pharmacokinetic study of memantine in healthy and renally impaired subjects publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.10.005 – volume: 4 start-page: 393 year: 2003 end-page: 398 ident: CR82 article-title: Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data publication-title: Curr Drug Metab doi: 10.2174/1389200033489389 – volume: 331 start-page: 263 year: 2005 end-page: 266 ident: CR134 article-title: Systematic comparison of four sources of drug information regarding adjustment of dose for renal function publication-title: Br Med J doi: 10.1136/bmj.38476.471088.3A – volume: 31 start-page: 410 year: 1996 end-page: 422 ident: CR38 article-title: Pharmacokinetics of opioids in renal dysfunction publication-title: Clin Pharmacokinet doi: 10.2165/00003088-199631060-00002 – volume: 298 start-page: 2038 year: 2007 end-page: 2047 ident: CR2 article-title: Prevalence of chronic kidney disease in the United States publication-title: JAMA doi: 10.1001/jama.298.17.2038 – volume: 19 start-page: 1113 year: 1995 end-page: 1119 ident: CR105 article-title: Hemodialyzer performance: a review of the trends over the past two decades publication-title: Artif Organs doi: 10.1111/j.1525-1594.1995.tb02272.x – volume: 42 start-page: 1193 year: 2003 end-page: 1211 ident: CR5 article-title: Principles and clinical application of assessing alterations in renal elimination pathways publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200342140-00002 – volume: 27 start-page: 665 year: 1980 end-page: 670 ident: CR35 article-title: Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient publication-title: Clin Pharmacol Ther – volume: 64 start-page: 1147 year: 2008 end-page: 1161 ident: CR53 article-title: Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction publication-title: Eur J Clin Pharmacol – ident: CR128 – volume: 81 start-page: 87 year: 1994 end-page: 93 ident: CR101 article-title: Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morhine publication-title: Anesthesiology doi: 10.1097/00000542-199409001-00086 – volume: 63 start-page: 837 year: 2007 end-page: 842 ident: CR100 article-title: Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-007-0329-x – volume: 144 start-page: 1067 year: 2005 end-page: 1077 ident: CR61 article-title: Effects of serum from patients with chronic renal failure on rat heaptic cytochrome P450 publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0706138 – volume: 6 start-page: 329 year: 1981 end-page: 345 ident: CR92 article-title: Drug metabolites in renal failure: pharmacokinetics and clinical implications publication-title: Clin Pharmacokinet doi: 10.2165/00003088-198106050-00001 – volume: 47 start-page: 637 year: 1999 end-page: 643 ident: CR13 article-title: Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1999.00938.x – volume: 24 start-page: 1227 year: 2007 end-page: 1251 ident: CR26 article-title: Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications publication-title: Pharm Res doi: 10.1007/s11095-007-9254-z – volume: 80 start-page: 235 year: 2006 end-page: 245 ident: CR52 article-title: Liver disease Selectivey modulates cytochrome P450- mediated metabolism drugs in liver publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2006.05.006 – year: 2004 ident: CR135 publication-title: British national formulary – volume: 17 start-page: 320 year: 2008 end-page: 325 ident: CR17 article-title: Estimating and measuring glomerular filtration rate in children publication-title: Curr Opin Nephrol Hypertens doi: 10.1097/MNH.0b013e3282fb77f2 – volume: 27 start-page: 816 year: 2005 end-page: 818 ident: CR90 article-title: Effect of hemodialysis on the metabolic clearance of 5-fluorouracil in a patient with end-stage renal failure publication-title: Ther Drug Monit doi: 10.1097/01.ftd.0000183384.89275.f4 – volume: 48 start-page: 693 year: 2008 end-page: 701 ident: CR124 article-title: Regulatory aspects of pharmacokinetic profiling in special populations publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200847110-00001 – volume: 32 start-page: 1239 year: 2004 end-page: 1246 ident: CR60 article-title: Effects of uremic toxins on hepatic uptake and metabolism of erythromycin publication-title: Drug Metab Disp doi: 10.1124/dmd.104.000521 – volume: 50 start-page: 91 year: 1996 end-page: 96 ident: CR75 article-title: Extrahepatic metabolism of propofol in man: possible contribution of gut wall and kidney publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280050074 – start-page: 633 year: 2000 end-page: 649 ident: CR31 article-title: Pharmacokinetics and pharmacodynamics of protein therapeutics publication-title: Peptides and protein drug analysis – volume: 109 start-page: 1 year: 2006 end-page: 11 ident: CR62 article-title: Effects of renal failure on drug transport and metabolism publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2005.05.010 – volume: 71 start-page: 282 year: 1993 end-page: 290 ident: CR47 article-title: Effect of renal failure on drug metabolism publication-title: Br J Anaesth doi: 10.1093/bja/71.2.282 – volume: 46 start-page: 677 year: 2007 end-page: 679 ident: CR20 article-title: Considerations in drug handling in renal disease publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200746080-00004 – volume: 78 start-page: S278 year: 2001 end-page: S281 ident: CR89 article-title: Hippurate participates in the correction of metabolic acidosis publication-title: Kidney Int Suppl doi: 10.1046/j.1523-1755.2001.07831.x – volume: 73 start-page: 475 year: 2003 end-page: 477 ident: CR50 article-title: Cytochrome P4502C9 activity in end-stage renal disease publication-title: Clin Pharmacol Ther doi: 10.1016/S0009-9236(03)00015-8 – volume: 44 start-page: 331 year: 2005 end-page: 347 ident: CR29 article-title: Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200544040-00001 – volume: 10 start-page: 189 year: 1981 end-page: 192 ident: CR71 article-title: Pharmacokinetics of ketoprofen in patients with chronic renal failure publication-title: Scand J Rheumatol doi: 10.3109/03009748109095297 – volume: 17 start-page: 2363 year: 2006 end-page: 2367 ident: CR67 article-title: Hemodialysis acutely improves hepatic CYP3A4 metabolic activity publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2006060610 – volume: 21 start-page: 1487 year: 1993 end-page: 1495 ident: CR12 article-title: Predictability of creatinine clearance estimates in critically ill patients publication-title: Crit Care Med doi: 10.1097/00003246-199310000-00016 – volume: 47 start-page: 565 year: 2008 end-page: 594 ident: CR51 article-title: Pharmacogenetics of oral anticoagulants—a basis for dose individualization publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200847090-00002 – volume: 28 start-page: 589 year: 1985 end-page: 595 ident: CR54 article-title: Antipyrine metabolite formation and excretion in patients with chronic renal insufficiency publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00544072 – ident: CR136 – volume: 64 start-page: 719 year: 2007 end-page: 721 ident: CR19 article-title: Drugs and the kidney: more than a question of dose publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2007.02987.x – volume: 60 start-page: 176 year: 2005 end-page: 182 ident: CR79 article-title: Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2005.02393.x – volume: ii start-page: 284 year: 1984 end-page: 285 ident: CR93 article-title: Be aware of renal function when prescribing morphine publication-title: Lancet doi: 10.1016/S0140-6736(84)90323-4 – volume: 137 start-page: 1039 year: 2002 end-page: 1046 ident: CR58 article-title: Down-regulation of hepatic cytochrome P450 in chronic renal failure: the role of uremic mediators publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0704951 – volume: 34 start-page: 621 year: 2006 end-page: 627 ident: CR66 article-title: Effect of chronic renal insufficiency on hepatic and renal UDP- glucuronyltransferases in rats publication-title: Drug Metab Disp doi: 10.1124/dmd.105.006601 – volume: 83 start-page: 898 year: 2008 end-page: 903 ident: CR64 article-title: Emerging evidence of the impact of kidney disease on drug metabolism and transport publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2008.59 – volume: 16 start-page: 31 year: 1976 end-page: 41 ident: CR8 article-title: Prediction of creatinine clearance from serum creatinine publication-title: Nephron doi: 10.1159/000180580 – volume: 26 start-page: 1421 year: 1992 end-page: 1428 ident: CR78 article-title: Contribution of the human kidney to the metabolic clearance of drugs publication-title: Ann Pharmacother – volume: 77 start-page: 542 year: 2005 end-page: 552 ident: CR133 article-title: Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.02.012 – volume: 63 start-page: 337 year: 1988 end-page: 341 ident: CR74 article-title: Glucuronidation of morphine in human kidney microsomes publication-title: Pharmacol Toxicol doi: 10.1111/j.1600-0773.1988.tb00965.x – volume: 2 start-page: 1235 year: 2007 end-page: 1240 ident: CR41 article-title: Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.01580407 – volume: 11 start-page: A0828 year: 2000 ident: CR10 article-title: A simplified equation to predict glomerular filtration rate from serum creatinine publication-title: J Am Soc Nephrol – volume: 32 start-page: 30 year: 1997 end-page: 57 ident: CR33 article-title: Principles of drug administration in renal insufficiency publication-title: Clin Pharmacokinet doi: 10.2165/00003088-199732010-00002 – volume: 85 start-page: 305 year: 2009 end-page: 311 ident: CR125 article-title: Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2008.208 – volume: 145 start-page: 117 year: 2003 end-page: 137 ident: CR69 article-title: Acyl glucuronide reactivity in perspective: biological consequences publication-title: Chem Biol Interact doi: 10.1016/S0009-2797(03)00020-6 – volume: 22 start-page: 11 year: 2005 end-page: 23 ident: CR83 article-title: Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system publication-title: Pharm Res doi: 10.1007/s11095-004-9004-4 – volume: 108 start-page: S18 year: 2008 end-page: S25 ident: CR106 article-title: Studies on peritoneal dialysis publication-title: Kidney Int Suppl doi: 10.1038/sj.ki.5002634 – volume: 17 start-page: 3041 year: 2006 end-page: 3048 ident: CR63 article-title: Role of parathyroid hormone in the down-regulation of liver cytochrome P450 in chronic renal failure publication-title: J A Soc Nephrol doi: 10.1681/ASN.2006010035 – volume: 320 start-page: 978 year: 2007 end-page: 985 ident: CR86 article-title: Down-regulation of intestinal drug transporters in chronic renal failure in rats publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.106.112631 – volume: 74 start-page: 580 year: 1996 end-page: 585 ident: CR88 article-title: Serum levels of 3-deoxyglucosoneand tissue contents of advanced glycation end-products are increased in streptozotocin-induced diabetic rats with nephropathy publication-title: Nephron doi: 10.1159/000189456 – volume: 81 start-page: 828 year: 2007 end-page: 832 ident: CR49 article-title: Effects of uptake and efflux transporter inhibition on erythromycin breath test results publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100148 – volume: 10 start-page: 87 year: 1982 end-page: 89 ident: CR70 article-title: Glucuronidation and disposition of drug glucuronides in patients with renal failure publication-title: Drug Metab Disp – ident: CR23 – volume: 7 start-page: 15 year: 2006 end-page: 21 ident: CR28 article-title: Early development of therapeutic biologics—pharmacokinetics publication-title: Curr Drug Metab doi: 10.2174/138920006774832604 – volume: 53 start-page: 21S year: 2002 end-page: 30S ident: CR39 article-title: The effect of age and renal and hepatic impairment on the Pharmacokinetics of sildenafil citrate publication-title: Br J Clin Pharmacol doi: 10.1046/j.0306-5251.2001.00029.x – volume: 51 start-page: 547 year: 2001 end-page: 555 ident: CR22 article-title: Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.2001.01390.x – volume: 130 start-page: 461 year: 1999 end-page: 470 ident: CR9 article-title: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation publication-title: Ann Intern Med – volume: 36 start-page: 124 year: 2008 end-page: 128 ident: CR87 article-title: Effects of chronic renal failure on liver drug transporters publication-title: Drug Metab Disp doi: 10.1124/dmd.107.018192 – volume: 13 start-page: 1579 year: 2002 end-page: 1585 ident: CR57 article-title: Downregulation of intestinal cytochrome P450 in chronic renal failure publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000017575.50319.77 – ident: CR110 – volume: 8 start-page: 1470 year: 1997 end-page: 1476 ident: CR43 article-title: The pathologic physiology of chronic Bright’s Disease: an exposition of the “intact nephron hypothesis” publication-title: J Am Soc Nephrol – volume: 73 start-page: 427 year: 2003 end-page: 434 ident: CR48 article-title: Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease publication-title: Clin Pharmacol Ther doi: 10.1016/S0009-9236(03)00056-0 – volume: 48 start-page: 494 year: 1999 end-page: 500 ident: CR73 article-title: Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a ‘futile cycle’ of elimination publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1999.00046.x – volume: 86 start-page: 1564 year: 2003 end-page: 1567 ident: CR103 article-title: Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain-barrier publication-title: J Neurochem doi: 10.1046/j.1471-4159.2003.01990.x – volume: 3 start-page: 355 year: 2008 ident: 678_CR115 publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.02920707 – volume: 74 start-page: 580 year: 1996 ident: 678_CR88 publication-title: Nephron doi: 10.1159/000189456 – volume: 2 start-page: 1235 year: 2007 ident: 678_CR41 publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.01580407 – volume: 51 start-page: 347 year: 1991 ident: 678_CR68 publication-title: Pharmacol Ther doi: 10.1016/0163-7258(91)90065-T – volume: 80 start-page: 235 year: 2006 ident: 678_CR52 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2006.05.006 – volume: 145 start-page: 117 year: 2003 ident: 678_CR69 publication-title: Chem Biol Interact doi: 10.1016/S0009-2797(03)00020-6 – ident: 678_CR128 – volume: 137 start-page: 1039 year: 2002 ident: 678_CR58 publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0704951 – volume: 144 start-page: 1067 year: 2005 ident: 678_CR61 publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0706138 – volume: 18 start-page: 381 year: 1990 ident: 678_CR116 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-199018050-00004 – volume: 1 start-page: 373 year: 1976 ident: 678_CR37 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-197601050-00004 – volume: 17 start-page: 3041 year: 2006 ident: 678_CR63 publication-title: J A Soc Nephrol doi: 10.1681/ASN.2006010035 – volume: 28 start-page: 589 year: 1985 ident: 678_CR54 publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00544072 – volume: 7 start-page: 675 year: 1998 ident: 678_CR7 publication-title: Curr Opin Nephrol Hypertens doi: 10.1097/00041552-199811000-00009 – volume: 42 start-page: 163 year: 1996 ident: 678_CR72 publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1996.03864.x – volume: 86 start-page: 1564 year: 2003 ident: 678_CR103 publication-title: J Neurochem doi: 10.1046/j.1471-4159.2003.01990.x – volume: 79 start-page: 134 year: 2006 ident: 678_CR44 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.10.005 – volume: 48 start-page: 693 year: 2008 ident: 678_CR124 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200847110-00001 – volume: 13 start-page: 1579 year: 2002 ident: 678_CR57 publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000017575.50319.77 – volume: 6 start-page: 329 year: 1981 ident: 678_CR92 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-198106050-00001 – ident: 678_CR137 – volume: 32 start-page: 30 year: 1997 ident: 678_CR33 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-199732010-00002 – volume: 284 start-page: F885 year: 2003 ident: 678_CR30 publication-title: Am J Renal Physiol doi: 10.1152/ajprenal.00123.2002 – volume: 17 start-page: 2363 year: 2006 ident: 678_CR67 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2006060610 – volume: 32 start-page: 377 year: 1987 ident: 678_CR95 publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00543973 – volume: 48 start-page: 613 year: 1990 ident: 678_CR77 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1990.203 – volume: 47 start-page: 637 year: 1999 ident: 678_CR13 publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1999.00938.x – volume: 81 start-page: 270 year: 2007 ident: 678_CR21 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100050 – volume: 13 start-page: 2140 year: 2002 ident: 678_CR11 publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000022011.35035.F3 – volume: 51 start-page: 547 year: 2001 ident: 678_CR22 publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.2001.01390.x – volume: 23 start-page: 1092 year: 2008 ident: 678_CR6 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfn028 – volume: ii start-page: 284 year: 1984 ident: 678_CR93 publication-title: Lancet doi: 10.1016/S0140-6736(84)90323-4 – volume: 73 start-page: 427 year: 2003 ident: 678_CR48 publication-title: Clin Pharmacol Ther doi: 10.1016/S0009-9236(03)00056-0 – ident: 678_CR132 – volume: 83 start-page: 241 year: 2002 ident: 678_CR102 publication-title: J Neurochem doi: 10.1046/j.1471-4159.2002.01177.x – volume: 10 start-page: 87 year: 1982 ident: 678_CR70 publication-title: Drug Metab Disp – volume: 19 start-page: 1113 year: 1995 ident: 678_CR105 publication-title: Artif Organs doi: 10.1111/j.1525-1594.1995.tb02272.x – volume: 78 start-page: 260 year: 2005 ident: 678_CR81 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.05.011 – volume: 331 start-page: 292 year: 2005 ident: 678_CR139 publication-title: Br Med J – volume: 20 start-page: 1617 year: 2005 ident: 678_CR18 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfh839 – volume: 77 start-page: 542 year: 2005 ident: 678_CR133 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2005.02.012 – volume: 42 start-page: 1193 year: 2003 ident: 678_CR5 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200342140-00002 – volume: 292 start-page: 1548 year: 1986 ident: 678_CR94 publication-title: Br Med J doi: 10.1136/bmj.292.6535.1548 – volume: 46 start-page: 677 year: 2007 ident: 678_CR20 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200746080-00004 – volume: 42 start-page: 1253 year: 2003 ident: 678_CR40 publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2003.08.027 – volume: 3 start-page: 459 year: 1983 ident: 678_CR45 publication-title: Int J Clin Pharmacol Res – volume: 40 start-page: 134 year: 1986 ident: 678_CR117 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1986.151 – volume: 64 start-page: 719 year: 2007 ident: 678_CR19 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2007.03073.x – ident: 678_CR112 – volume: 354 start-page: 2473 year: 2006 ident: 678_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMra054415 – volume: 41 start-page: 2845 year: 1987 ident: 678_CR97 publication-title: Life Sci doi: 10.1016/0024-3205(87)90431-0 – volume: 27 start-page: 816 year: 2005 ident: 678_CR90 publication-title: Ther Drug Monit doi: 10.1097/01.ftd.0000183384.89275.f4 – volume: 46 start-page: 389 year: 1994 ident: 678_CR127 publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00191898 – start-page: 187 volume-title: Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring year: 2006 ident: 678_CR34 – volume: 94 start-page: 2569 year: 1999 ident: 678_CR120 publication-title: Blood doi: 10.1182/blood.V94.8.2569.420k13_2569_2574 – start-page: 1787 volume-title: Goodman & Gilman’s The Pharmacological Basis of Therapeutics year: 2006 ident: 678_CR1 – volume: 19 start-page: 1352 year: 2008 ident: 678_CR65 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2007090974 – volume: 27 start-page: 665 year: 1980 ident: 678_CR35 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1980.94 – volume: 38 start-page: 1 year: 2005 ident: 678_CR16 publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2004.09.025 – volume: 53 start-page: 21S year: 2002 ident: 678_CR39 publication-title: Br J Clin Pharmacol doi: 10.1046/j.0306-5251.2001.00029.x – volume: 42 start-page: 1043 year: 2003 ident: 678_CR123 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200342120-00003 – volume: 47 start-page: 487 year: 2008 ident: 678_CR130 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200847080-00001 – volume: 73 start-page: 475 year: 2003 ident: 678_CR50 publication-title: Clin Pharmacol Ther doi: 10.1016/S0009-9236(03)00015-8 – volume: 71 start-page: 282 year: 1993 ident: 678_CR47 publication-title: Br J Anaesth doi: 10.1093/bja/71.2.282 – volume: 63 start-page: 837 year: 2007 ident: 678_CR100 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-007-0329-x – volume: 298 start-page: 2038 year: 2007 ident: 678_CR2 publication-title: JAMA doi: 10.1001/jama.298.17.2038 – volume: 60 start-page: 176 year: 2005 ident: 678_CR79 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2005.02393.x – volume: 44 start-page: 137 year: 2004 ident: 678_CR24 publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev.pharmtox.44.101802.121856 – volume: 47 start-page: 333 year: 2008 ident: 678_CR129 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200847050-00004 – ident: 678_CR53 doi: 10.1007/s00228-008-0553-z – volume: 12 start-page: 326 year: 2001 ident: 678_CR56 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.V122326 – volume: 7 start-page: 15 year: 2006 ident: 678_CR28 publication-title: Curr Drug Metab doi: 10.2174/138920006774832604 – volume-title: Clinical pharmacokinetics: concepts and applications year: 1995 ident: 678_CR32 – volume: 31 start-page: 410 year: 1996 ident: 678_CR38 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-199631060-00002 – volume: 78 start-page: S278 year: 2001 ident: 678_CR89 publication-title: Kidney Int Suppl doi: 10.1046/j.1523-1755.2001.07831.x – volume: 68 start-page: 667 year: 2000 ident: 678_CR98 publication-title: Clin Pharmacol Ther doi: 10.1067/mcp.2000.111934 – volume: 34 start-page: 1336 year: 2006 ident: 678_CR84 publication-title: Drug Metab Disp doi: 10.1124/dmd.106.009258 – volume: 51 start-page: 465 year: 1992 ident: 678_CR126 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1992.47 – volume: 26 start-page: 1421 year: 1992 ident: 678_CR78 publication-title: Ann Pharmacother doi: 10.1177/106002809202601116 – volume: 331 start-page: 263 year: 2005 ident: 678_CR134 publication-title: Br Med J doi: 10.1136/bmj.38476.471088.3A – start-page: 750 volume-title: Replacement of Renal Function by Dialysis year: 1996 ident: 678_CR111 doi: 10.1007/978-0-585-36947-1_30 – volume: 8 start-page: 1470 year: 1997 ident: 678_CR43 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.V891470 – volume: 320 start-page: 978 year: 2007 ident: 678_CR86 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.106.112631 – volume: 81 start-page: 87 year: 1994 ident: 678_CR101 publication-title: Anesthesiology doi: 10.1097/00000542-199407000-00013 – volume: 130 start-page: 461 year: 1999 ident: 678_CR9 publication-title: Ann Intern Med doi: 10.7326/0003-4819-130-6-199903160-00002 – volume: 36 start-page: 124 year: 2008 ident: 678_CR87 publication-title: Drug Metab Disp doi: 10.1124/dmd.107.018192 – ident: 678_CR110 – volume: 24 start-page: 2575 year: 2008 ident: 678_CR131 publication-title: Curr Med Res Opin doi: 10.1185/03007990802312807 – start-page: 115 volume-title: Drug absorption—Proc Edinburgh Int Conf year: 1981 ident: 678_CR36 – volume: 105 start-page: 225 year: 2002 ident: 678_CR118 publication-title: Thromb Res doi: 10.1016/S0049-3848(02)00031-2 – volume: 109 start-page: 1 year: 2006 ident: 678_CR62 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2005.05.010 – volume: 63 start-page: 509 year: 2007 ident: 678_CR14 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2007.02917.x – volume: 10 start-page: 189 year: 1981 ident: 678_CR71 publication-title: Scand J Rheumatol doi: 10.3109/03009748109095297 – volume: 27 start-page: 414 year: 2004 ident: 678_CR108 publication-title: Int J Artif Organs doi: 10.1177/039139880402700511 – volume: 34 start-page: 621 year: 2006 ident: 678_CR66 publication-title: Drug Metab Disp doi: 10.1124/dmd.105.006601 – volume: 50 start-page: 91 year: 1996 ident: 678_CR75 publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280050074 – volume: 14 start-page: 17 year: 2007 ident: 678_CR114 publication-title: Adv Chronic Kidney Dis doi: 10.1053/j.ackd.2007.03.004 – ident: 678_CR91 doi: 10.1254/jphs.08042FP – volume: 55 start-page: 1005 year: 1998 ident: 678_CR76 publication-title: Biochem Pharmacol doi: 10.1016/S0006-2952(97)00534-0 – volume: 28 start-page: 1317 year: 2000 ident: 678_CR55 publication-title: Drug Metab Disp – volume: 64 start-page: 738 year: 2007 ident: 678_CR113 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2007.02963.x – volume: 26 start-page: 305 year: 2004 ident: 678_CR119 publication-title: Ther Drug Monit doi: 10.1097/00007691-200406000-00015 – volume: 83 start-page: 1064 year: 2008 ident: 678_CR3 publication-title: Mayo Clin Proc doi: 10.4065/83.9.1064 – volume: 4 start-page: 91 year: 2003 ident: 678_CR59 publication-title: Curr Drug Metab doi: 10.2174/1389200033489532 – volume: 30 start-page: 991 year: 2007 ident: 678_CR122 publication-title: Drug Saf doi: 10.2165/00002018-200730110-00001 – volume: 11 start-page: 178 year: 2007 ident: 678_CR121 publication-title: Hemodial Int doi: 10.1111/j.1542-4758.2007.00166.x – ident: 678_CR136 – ident: 678_CR109 – start-page: 82 volume-title: Applied pharmacokinetics and pharmacodynamics—principles of therapeutic drug monitoring year: 2006 ident: 678_CR42 – volume: 97 start-page: 814 year: 2002 ident: 678_CR104 publication-title: Anesthesiology doi: 10.1097/00000542-200210000-00011 – volume: 16 start-page: 31 year: 1976 ident: 678_CR8 publication-title: Nephron doi: 10.1159/000180580 – volume: 48 start-page: 494 year: 1999 ident: 678_CR73 publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1999.00046.x – volume: 81 start-page: 194 year: 2007 ident: 678_CR85 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100038 – volume: 22 start-page: 11 year: 2005 ident: 678_CR83 publication-title: Pharm Res doi: 10.1007/s11095-004-9004-4 – volume: 54 start-page: 158 year: 1993 ident: 678_CR96 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1993.127 – volume: 11 start-page: A0828 year: 2000 ident: 678_CR10 publication-title: J Am Soc Nephrol – volume: 47 start-page: 565 year: 2008 ident: 678_CR51 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200847090-00002 – volume: 39 start-page: 1 year: 1987 ident: 678_CR27 publication-title: Pharmacol Rev – volume-title: British national formulary year: 2004 ident: 678_CR135 – volume: 63 start-page: 337 year: 1988 ident: 678_CR74 publication-title: Pharmacol Toxicol doi: 10.1111/j.1600-0773.1988.tb00965.x – ident: 678_CR23 – volume: 8 start-page: 7 year: 1986 ident: 678_CR46 publication-title: Am J Kidney Dis doi: 10.1016/S0272-6386(86)80148-2 – volume: 40 start-page: 153 year: 2007 ident: 678_CR15 publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2006.10.014 – volume: 83 start-page: 898 year: 2008 ident: 678_CR64 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2008.59 – volume: 585 start-page: 245 year: 2008 ident: 678_CR25 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2008.02.085 – volume: 4 start-page: 393 year: 2003 ident: 678_CR82 publication-title: Curr Drug Metab doi: 10.2174/1389200033489389 – volume: 108 start-page: S18 year: 2008 ident: 678_CR106 publication-title: Kidney Int Suppl doi: 10.1038/sj.ki.5002634 – volume: 81 start-page: 828 year: 2007 ident: 678_CR49 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100148 – volume: 32 start-page: 1239 year: 2004 ident: 678_CR60 publication-title: Drug Metab Disp doi: 10.1124/dmd.104.000521 – volume: 18 start-page: 183 year: 1984 ident: 678_CR80 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1984.tb02451.x – start-page: 633 volume-title: Peptides and protein drug analysis year: 2000 ident: 678_CR31 – volume: 85 start-page: 305 year: 2009 ident: 678_CR125 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2008.208 – volume: 44 start-page: 331 year: 2005 ident: 678_CR29 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200544040-00001 – volume: 1 start-page: 83 year: 2005 ident: 678_CR99 publication-title: J Opioid Manag doi: 10.5055/jom.2005.0021 – volume: 21 start-page: 1487 year: 1993 ident: 678_CR12 publication-title: Crit Care Med doi: 10.1097/00003246-199310000-00016 – volume: 17 start-page: 320 year: 2008 ident: 678_CR17 publication-title: Curr Opin Nephrol Hypertens doi: 10.1097/MNH.0b013e3282fb77f2 – volume: 24 start-page: 1227 year: 2007 ident: 678_CR26 publication-title: Pharm Res doi: 10.1007/s11095-007-9254-z – volume: 7 start-page: 149 year: 2004 ident: 678_CR107 publication-title: J Artif Organs doi: 10.1007/s10047-004-0257-9 – ident: 678_CR138 – reference: 8042814 - Anesthesiology. 1994 Jul;81(1):87-93 – reference: 2826951 - Life Sci. 1987 Dec 28;41(26):2845-9 – reference: 19020495 - Clin Pharmacol Ther. 2009 Mar;85(3):305-11 – reference: 17361125 - Clin Pharmacol Ther. 2007 Jun;81(6):828-32 – reference: 16085315 - Pharmacol Ther. 2006 Jan;109(1-2):1-11 – reference: 12357145 - Anesthesiology. 2002 Oct;97(4):814-9 – reference: 7037261 - Clin Pharmacokinet. 1981 Sep-Oct;6(5):329-45 – reference: 6124391 - Drug Metab Dispos. 1982 Jan-Feb;10(1):87-9 – reference: 16698890 - Drug Metab Dispos. 2006 Aug;34(8):1336-44 – reference: 16306860 - Ther Drug Monit. 2005 Dec;27(6):816-8 – reference: 6147317 - Int J Clin Pharmacol Res. 1983;3(6):459-74 – reference: 3524205 - Am J Kidney Dis. 1986 Jul;8(1):7-17 – reference: 18388866 - Clin Pharmacol Ther. 2008 Jun;83(6):898-903 – reference: 12676733 - Am J Physiol Renal Physiol. 2003 May;284(5):F885-92 – reference: 17655374 - Clin Pharmacokinet. 2007;46(8):677-9 – reference: 16042671 - Br J Clin Pharmacol. 2005 Aug;60(2):176-82 – reference: 15286055 - Drug Metab Dispos. 2004 Nov;32(11):1239-46 – reference: 17473959 - Pharm Res. 2007 Jul;24(7):1227-51 – reference: 12423235 - J Neurochem. 2002 Oct;83(2):241-8 – reference: 9605424 - Biochem Pharmacol. 1998 Apr 1;55(7):1005-12 – reference: 10515859 - Blood. 1999 Oct 15;94(8):2569-74 – reference: 17192770 - Clin Pharmacol Ther. 2007 Feb;81(2):194-204 – reference: 8579523 - Artif Organs. 1995 Nov;19(11):1113-9 – reference: 6146831 - Lancet. 1984 Aug 4;2(8397):284-5 – reference: 15905228 - BMJ. 2005 Jul 30;331(7511):263 – reference: 16454690 - Curr Drug Metab. 2006 Jan;7(1):15-21 – reference: 10075613 - Ann Intern Med. 1999 Mar 16;130(6):461-70 – reference: 18417721 - J Am Soc Nephrol. 2008 Jul;19(7):1352-9 – reference: 16760447 - N Engl J Med. 2006 Jun 8;354(23):2473-83 – reference: 1792239 - Pharmacol Ther. 1991;51(3):347-69 – reference: 15855207 - Nephrol Dial Transplant. 2005 Aug;20(8):1617-22 – reference: 15828849 - Clin Pharmacokinet. 2005;44(4):331-47 – reference: 11158222 - J Am Soc Nephrol. 2001 Feb;12(2):326-32 – reference: 17488361 - Br J Clin Pharmacol. 2007 May;63(5):509-11 – reference: 9012555 - Clin Pharmacokinet. 1997 Jan;32(1):30-57 – reference: 11927128 - Thromb Res. 2002 Feb 1;105(3):225-31 – reference: 16899515 - J Am Soc Nephrol. 2006 Sep;17(9):2363-7 – reference: 15558337 - J Artif Organs. 2004;7(3):149-54 – reference: 18762933 - Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61 – reference: 18845914 - J Pharmacol Sci. 2008 Oct;108(2):157-63 – reference: 12039987 - J Am Soc Nephrol. 2002 Jun;13(6):1579-85 – reference: 18078474 - Br J Clin Pharmacol. 2007 Dec;64(6):719-21 – reference: 16415115 - Drug Metab Dispos. 2006 Apr;34(4):621-7 – reference: 3609116 - Eur J Clin Pharmacol. 1987;32(4):377-82 – reference: 1017154 - Clin Pharmacokinet. 1976;1(5):373-84 – reference: 17940133 - Drug Metab Dispos. 2008 Jan;36(1):124-8 – reference: 18235142 - Clin J Am Soc Nephrol. 2008 Mar;3(2):355-61 – reference: 8938685 - Nephron. 1996;74(3):580-5 – reference: 11169026 - Kidney Int Suppl. 2001 Feb;78:S278-81 – reference: 6593092 - Br J Clin Pharmacol. 1984 Aug;18(2):183-93 – reference: 12429576 - Br J Pharmacol. 2002 Dec;137(7):1039-46 – reference: 14529371 - Curr Drug Metab. 2003 Oct;4(5):393-8 – reference: 1563216 - Clin Pharmacol Ther. 1992 Apr;51(4):465-73 – reference: 8354025 - Clin Pharmacol Ther. 1993 Aug;54(2):158-67 – reference: 17619868 - Eur J Clin Pharmacol. 2007 Sep;63(9):837-42 – reference: 9294841 - J Am Soc Nephrol. 1997 Sep;8(9):1470-6 – reference: 11422014 - Br J Clin Pharmacol. 2001 Jun;51(6):547-55 – reference: 18698879 - Clin Pharmacokinet. 2008;47(9):565-94 – reference: 1477449 - Ann Pharmacother. 1992 Nov;26(11):1421-8 – reference: 15771225 - Pharm Res. 2005 Jan;22(1):11-23 – reference: 8123408 - Br J Anaesth. 1993 Aug;71(2):282-90 – reference: 10583018 - Br J Clin Pharmacol. 1999 Oct;48(4):494-500 – reference: 15700027 - Br J Pharmacol. 2005 Apr;144(8):1067-77 – reference: 7957530 - Eur J Clin Pharmacol. 1994;46(5):389-91 – reference: 18611060 - Clin Pharmacokinet. 2008;47(8):487-513 – reference: 18408486 - Curr Opin Nephrol Hypertens. 2008 May;17(3):320-5 – reference: 18379543 - Kidney Int Suppl. 2008 Apr;(108):S18-25 – reference: 18775206 - Mayo Clin Proc. 2008 Sep;83(9):1064-9 – reference: 18417112 - Eur J Pharmacol. 2008 May 13;585(2-3):245-55 – reference: 12950465 - J Neurochem. 2003 Sep;86(6):1564-7 – reference: 18399714 - Clin Pharmacokinet. 2008;47(5):333-41 – reference: 14744242 - Annu Rev Pharmacol Toxicol. 2004;44:137-66 – reference: 3554275 - Pharmacol Rev. 1987 Mar;39(1):1-47 – reference: 12732843 - Clin Pharmacol Ther. 2003 May;73(5):427-34 – reference: 17973538 - Drug Saf. 2007;30(11):991-4 – reference: 12732848 - Clin Pharmacol Ther. 2003 May;73(5):475-7 – reference: 12138147 - J Am Soc Nephrol. 2002 Aug;13(8):2140-4 – reference: 18674408 - Curr Med Res Opin. 2008 Sep;24(9):2575-85 – reference: 17603971 - Adv Chronic Kidney Dis. 2007 Jul;14(3):e17-26 – reference: 18359868 - Nephrol Dial Transplant. 2008 Apr;23(4):1092-5 – reference: 4043202 - Eur J Clin Pharmacol. 1985;28(5):589-95 – reference: 16413248 - Clin Pharmacol Ther. 2006 Jan;79(1):134-43 – reference: 17986697 - JAMA. 2007 Nov 7;298(17):2038-47 – reference: 1244564 - Nephron. 1976;16(1):31-41 – reference: 3087512 - Br Med J (Clin Res Ed). 1986 Jun 14;292(6535):1548-9 – reference: 12686489 - Chem Biol Interact. 2003 May 6;145(2):117-37 – reference: 15167633 - Ther Drug Monit. 2004 Jun;26(3):305-10 – reference: 2249372 - Clin Pharmacol Ther. 1990 Dec;48(6):613-8 – reference: 17021269 - J Am Soc Nephrol. 2006 Nov;17(11):3041-8 – reference: 3731676 - Clin Pharmacol Ther. 1986 Aug;40(2):134-9 – reference: 11879256 - Br J Clin Pharmacol. 2002;53 Suppl 1:21S-30S – reference: 2185908 - Clin Pharmacokinet. 1990 May;18(5):381-408 – reference: 16952490 - Clin Pharmacol Ther. 2006 Sep;80(3):235-45 – reference: 15961985 - Clin Pharmacol Ther. 2005 Jun;77(6):542-52 – reference: 15202820 - Int J Artif Organs. 2004 May;27(5):414-9 – reference: 8739817 - Eur J Clin Pharmacol. 1996;50(1-2):91-6 – reference: 12678690 - Curr Drug Metab. 2003 Apr;4(2):91-103 – reference: 17913970 - Clin J Am Soc Nephrol. 2007 Nov;2(6):1235-40 – reference: 18840025 - Clin Pharmacokinet. 2008;47(11):693-701 – reference: 17234172 - Clin Biochem. 2007 Feb;40(3-4):153-61 – reference: 17135344 - J Pharmacol Exp Ther. 2007 Mar;320(3):978-85 – reference: 11180027 - Clin Pharmacol Ther. 2000 Dec;68(6):667-76 – reference: 16153397 - Clin Pharmacol Ther. 2005 Sep;78(3):260-77 – reference: 11038159 - Drug Metab Dispos. 2000 Nov;28(11):1317-20 – reference: 9864664 - Curr Opin Nephrol Hypertens. 1998 Nov;7(6):675-80 – reference: 3148914 - Pharmacol Toxicol. 1988 Nov;63(5):337-41 – reference: 17403168 - Hemodial Int. 2007 Apr;11(2):178-89 – reference: 8403957 - Crit Care Med. 1993 Oct;21(10):1487-95 – reference: 14655198 - Am J Kidney Dis. 2003 Dec;42(6):1253-9 – reference: 17662093 - Br J Clin Pharmacol. 2007 Dec;64(6):738-44 – reference: 8968655 - Clin Pharmacokinet. 1996 Dec;31(6):410-22 – reference: 8864313 - Br J Clin Pharmacol. 1996 Aug;42(2):163-9 – reference: 17259951 - Clin Pharmacol Ther. 2007 Feb;81(2):270-83 – reference: 10383541 - Br J Clin Pharmacol. 1999 Jun;47(6):637-43 – reference: 7371364 - Clin Pharmacol Ther. 1980 May;27(5):665-70 – reference: 17319252 - J Opioid Manag. 2005 May-Jun;1(2):83-90 – reference: 14606929 - Clin Pharmacokinet. 2003;42(14):1193-211 – reference: 15607309 - Clin Biochem. 2005 Jan;38(1):1-8 – reference: 12959635 - Clin Pharmacokinet. 2003;42(12):1043-57 – reference: 7291952 - Scand J Rheumatol. 1981;10(3):189-92 |
| SSID | ssj0015903 |
| Score | 2.367572 |
| SecondaryResourceType | review_article |
| Snippet | Introduction Chronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the... Introduction Chronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the... Chronic kidney disease is a common, progressive illness that is becoming a global public health problem. In patients with kidney dysfunction, the renal... |
| SourceID | proquest pubmed pascalfrancis crossref springer fao |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 757 |
| SubjectTerms | Biological and medical sciences Biomarkers - blood Biomedical and Life Sciences Biomedicine Creatinine - blood Dosage adjustment Dose-Response Relationship, Drug Drug Administration Schedule Drug therapy Glomerular Filtration Rate Hepatorenal Syndrome - metabolism Humans Kidney - metabolism Kidney diseases Kidney Failure, Chronic - blood Kidney Failure, Chronic - metabolism Kidney Function Tests Mathematical Computing Medical sciences Metabolic Clearance Rate Non-renal drug clearance Pharmacokinetic/pharmacodynamic processes Pharmacokinetics Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Renal Dialysis Renal drug clearance Renal dysfunction Review Article Severity of Illness Index Side effects |
| SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7RcuGCeDe0FB9QD1BLduw48bFCVAUJVImu1Jvl2A6Coixqdg_77zuT16qiReIY2XFif3584xl_BnhnPK66KpWc1MTRQKkkr4LSXNmEfCJFERsyFL9-M2cL_eWyuBzPcXdTtPvkkuxn6vmwWy_VwvvNfJxhebUDDwsy3bETL_KT2XVQWDEq7UpubDm7Mu8q4tZitNP4JYVG-g5bpxmutbiLd_7lM-2XotMn8HjkkOxkAP0pPEjtMzg6H0SoN8fsYnumqjtmR-x8K0-9eQ6fp8crJJiUhfk2srikCDPm46911wees58tG0VXO0a7tew60VfjpqO1kPB8AYvTTxcfz_h4oQIPurQrniekZ6a2UQdSVS9sjHUyPphSxRCkUKGqCmR4AQeyCKIWebDSRqVDUUkZgnoJu-2yTXvADKaoJhQGgUXG5a2um4jUrDEml6EyGYipZV0Y1cbp0ovfbtZJ7sFwCIYjMFyVwfv5lT-D1Ma_Mu8hXM7_wKnQLb7n5ICVyKbKXGdweAvDuTC0vmgPXGSwP4HqxhHbOZKOKy32nwzezqk41Mh_4tu0XHdOG-S6xoj7c6D1hT8hsfavhr6yrYgttMIJPYMPU-fZfvveWr7-r9z78GjwdVF44gHsrq7X6Q1SplV92A-RG-0WCO4 priority: 102 providerName: Springer Nature |
| Title | Pharmacokinetics and dosage adjustment in patients with renal dysfunction |
| URI | https://link.springer.com/article/10.1007/s00228-009-0678-8 https://www.ncbi.nlm.nih.gov/pubmed/19543887 https://www.proquest.com/docview/214479001 https://www.proquest.com/docview/46326660 https://www.proquest.com/docview/67516516 |
| Volume | 65 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED-x7YUXxPfCoPgB7QFmYefDSZ5QQR0DxFTBKpUnK7EdBEzJtrQP_e-5S5xUE2xPURO3jn323e98198BvFIFWt3IpZzYxNFBySTPTBTzKHeIJ5wVtiJH8eupOlnEn5fJ0ufmtD6tctCJnaK2jaEz8rdE7ZXmqFTfXVxyKhpFwVVfQWMH9oi5jDK60uXob6GhFp5zV3KVp2NQU3QcoiFRM1NkANU1z66ZpZ2qaChJsmhxnqq-wMX_EOg_0dPOKB3fh3seTbJpL_4HcMfVD-Fw3tNRb47Y2fbfVe0RO2TzLVH15hF8Gj7-QahJTVhRW2YbyjVjhf29brsUdParZp5-tWV0bsuuHPVqNy1ZRZLsY1gcz84-nHBfWoEbnMUVDx0CNVXmNjbEr57k1pZOFUalkTVGishkWYJYz-CWFkaUIjS5zG0UmyST0pjoCezWTe32gSl8ElUmUShixF5FHpeVRZBWKRVKk6kAxDCz2njecSp_ca5HxuROGBqFoUkYOgvg9fiVi55047bG-yguXfxEpagX30MKxUrEVWkYBzC5JsPxx9APo9NwEcDBIFTt926rx5UWwMvxKW46iqQUtWvWrY4Vol6lxM0t0A_Dl5A4-qf9WtkOJE_iCFV7AG-GxbPt-8ZRPrv1TQ_gbh_losTE57C7ulq7FwiWVuWk2xIT2Jt-_PFlhtf3s9P5N7y7CKd_AZC1D_g |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB612wNcEO-GQusD9ACNcF5OfECIR6td2q5WsCv15ia2g2hRUppdof1R_Edm8lpV0N56jOI8nBnPfOOZfAPwUqTodQMbu8QmjgFK4rmJDkI3kBbxhDXc5BQoHo_FcBZ-OYlO1uBP9y8MlVV2NrE21KbUtEf-lqi9YolG9f3FL5eaRlFyteug0WjFoV3-xoitejf6jOJ95fsH-9NPQ7dtKuBqvH7u-hYhisikCTUxi0fSmMyKVIs4MFp7PNBJEiHK0ajMXPOM-1p60gShjhLP0zrA-67DRhhgJDOAjY_748nXPm0RSd6y_HqukHGfRuU1a6lPZNCUi0AH4SZXHOF6npZUlplWKJm8aanxP8z7T762doMH9-Fei1_Zh0bhHsCaLR7C7qQhwF7usenqf65qj-2yyYoae_kIRt3hOYJbGsLSwjBTUnUbS83ZoqqL3tmPgrWErxWjnWJ2aempZlmRHyZdegyzW_nuT2BQlIXdBCbwTJDrSKBSIdpLZZjlBmFhLoTv6UQ4wLsvq3TLdE4NN36qnqO5FoZCYSgShkoceN1fctHQfNw0eBPFpdLvaIbV7JtPyV8PkVzshw5sX5FhfzOM_Gj_nTuw1QlVtdaiUr1uO7DTn8VlTrmbtLDlolKhQJwtBL9-BEZ--BIezv5poyuricgoDNCZOPCmU57Vs6-d5bMb33QH7gynx0fqaDQ-3IK7TY6NyiKfw2B-ubAvEKrNs-12gTA4ve01-RcNR0kk |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB61RUJcKt4Npa0P0AM0wo4TJzlUCFFWXQrVSnSlvZnEdlABJaXZFdqfxr9jJq9VBe2tx1W8TpyZ8XzjmXwD8EJl6HWli31iE8cAJRF-YmToy9QhnnCW24ICxc-n6ngafpxFszX4038LQ2WV_Z7YbNS2MnRG_oaoveKUCIOKripicjR6e_HLpwZSlGjtu2m0GnLilr8xeqsPx0co6pdBMPpw9v7Y7xoM-AbnmvuBQ7ii8tSGhljGo9Ta3KnMqFhaYwSXJkkiRDwGFZsbnvPApCK1MjRRIoQxEuddhzuxjASZWDwbYj0ECbzj-xW-SuMhocob_tKAaKEpK4Guwk-uuMT1IquoQDOrUUZF21zjf-j3n8xt4xBH92GzQ7LsXat6D2DNlQ9hf9JSYS8P2Nnqy676gO2zyYoke_kIxv3PHwhzaQjLSstsRXVuLLPfF3VT_s7OS9ZRv9aMzozZpaO72mVNHpm06jFMb-WtP4GNsirdFjCFV2RhIoXqhbgvS8O8sAgQC6UCYRLlAe_frDYd5zm13vipB7bmRhgahaFJGDrx4NXwl4uW8OOmwVsoLp19ww1ZT78ElAYWiOniIPRg94oMh8kwBqSTeO7Bdi9U3e0btR603IO94SoaPGVxstJVi1qHChG3Uvz6ERgD4kMIXP3TVldWC0mjUKJb8eB1rzyre1-7ymc3Puke3EVL1J_GpyfbcK9NtlF95HPYmF8u3A5itnm-21gHg6-3bY5_ARB2S_Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+and+dosage+adjustment+in+patients+with+renal+dysfunction&rft.jtitle=European+journal+of+clinical+pharmacology&rft.au=Verbeeck%2C+Roger+K.&rft.au=Musuamba%2C+Flora+T.&rft.date=2009-08-01&rft.issn=0031-6970&rft.eissn=1432-1041&rft.volume=65&rft.issue=8&rft.spage=757&rft.epage=773&rft_id=info:doi/10.1007%2Fs00228-009-0678-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00228_009_0678_8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6970&client=summon |